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Abstract	  In	  the	  field	  of	  anti-­‐cancer	  drug	  delivery,	  nanoparticles	  have	  become	  an	  active	  topic	  of	  research.	  Nanoparticles	  made	  of	  biodegradable	  materials	  such	  as	  polylactic	  acid,	  proteins,	  and	  polysaccharides	  have	  been	   reported	   for	  delivery	  applications.	  Among	  all	   the	   studies,	  polysaccharide-­‐based	   systems	   are	   gaining	   increasing	   attention	   due	   to	   their	   low	   toxicity,	  great	   abundance,	   and	   high	   biocompatibility.	   However,	   relatively	   few	   starch-­‐based	  nanoparticle	   delivery	   systems	   have	   been	   reported.	   In	   addition,	   most	   previous	   work	  employed	  only	   small-­‐scale	   lab	   synthesized	   starch	  nanoparticles,	  which	  were	  made	  under	  various	  condition	  using	  different	  crosslinking	  agents.	  Therefore,	  they	  may	  have	  large	  batch-­‐to-­‐batch	   variation.	   This	   thesis	   reports	   a	   starch	   nanoparticle	   delivery	   system	  designed	   to	  target	   cancer	   cells.	   A	   commercially	   available	   starch	   nanoparticle	   material	   named	  EcoSphereTM	   was	   modified	   with	   aptamers	   to	   achieve	   active	   targeting.	   Our	   EcoSphereTM	  nanoparticles	  (ENP)	  were	  made	  in	  very	  large	  scale	  and	  its	  modification	  scheme	  is	  divided	  into	   initial	   oxidation	   and	   subsequent	   aptamer	   conjugation.	   	   ENPs	   were	   first	   subject	   to	  TEMPO-­‐mediated	  oxidation	  to	  selectively	  oxidize	  its	  C6	  hydroxyl	  group	  into	  carboxyl	  group.	  Partially	   oxidized	   ENPs	   were	   confirmed	   and	   characterized	   through	   spectroscopic	  measurements,	   including	   NMR	   and	   dynamic	   light	   scattering.	   	   ENPs	   of	   various	   oxidation	  levels	  (1%,	  2%,	  5%,	  10%,	  and	  20%)	  were	  then	  tested	  for	  conjugation	  efficiency	  using	  dye	  molecules	  and	  control	  DNA,	  and	  only	  the	  20%	  oxidized	  ENPs	  show	  minor	  DNA	  conjugation.	  DNA	   coupling	   procedure	   was	   then	   optimized	   and	   aptamer	   conjugation	   efficiency	   was	  improved	  to	  >80%	  by	  reacting	  at	  elevated	  temperatures	  and	  in	  slightly	  acidic	  environment.	  The	   fully	   modified	   ENPs	   were	   then	   subject	   to	   two	   cellular	   assays	   to	   evaluate	   cellular	  internalization	  and	  vehicle	  selectivity.	  Aptamer-­‐modified	  ENPs	  show	  clear	   internalization	  and	   dye-­‐modified	   ENPs	   also	   shows	   significant	   internalization.	   Vehicle	   selectivity	   was	  demonstrated	   through	   preferential	   uptake	   of	   AS1411-­‐modified	   ENPs	   over	   sgc8-­‐modified	  ENPs,	  where	  sgc8	  is	  a	  control	  aptamer	  that	  does	  not	  target	  the	  HeLa	  cells.	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Chapter	  1.	  Introduction	  
1.1 Cancer	  	  A	   tumor	   is	   a	   mass	   accumulation	   of	   abnormal	   tissue	   growth.	   [1]	   According	   to	   World	  Cancer	   Report	   2014,	   cancer	   related	   deaths	   exceeded	   eight	  million	   counts	  world-­‐wide	   in	  2012,	   and	  majority	   of	   these	   deaths	   were	   caused	   by	  metastatic	   cancers.	   [2]	   The	   previous	  report	  published	  in	  2008	  also	  indicated	  that	  cancers	  accounted	  for	  over	  12%	  of	  all	  deaths	  each	  year	  and	   is	   currently	   the	   leading	  cause	  of	  death	   in	   the	  developed	  countries	  and	   the	  second	  leading	  cause	  of	  death	  in	  the	  developing	  countries.	  [3]	  Cancer	  does	  not	  only	  threaten	  the	  well-­‐being	  of	   individuals,	   it	  also	  has	  tremendous	  negative	  economic	  impact.	   In	  United	  States	   alone,	   more	   than	   $100	   billion	   were	   spent	   annually	   on	   direct	   medical	   costs	   with	  another	  $123	  billion	  lost	  due	  to	  loss	  of	  productivity.	  [4]	  It	  is	  obvious	  that	  cancer	  is	  a	  major	  global	   problem.	   With	   such	   extensive	   repercussions,	   large	   amounts	   of	   resources	   were	  invested	  to	  fight	  cancer.	   It	   is	  true	  that	  the	  overall	  cancer	  mortality	  rate	  has	  declined	  over	  the	   past	   few	   decades	   (Fig.1),	   but	   unfortunately,	   the	   incident	   rate	   is	   still	   on	   the	   rise.	   [4]	  Research	   has	   attributed	   the	   alarming,	   increasing	   trend	   largely	   to	   the	   aging	   of	   the	  population.	  Adaptation	  of	  unhealthy	  lifestyles	  such	  as	  smoking,	  alcohol	  consumption,	  poor	  diet,	  and	  the	  lack	  of	  physical	  activity	  further	  increase	  the	  burden.	  [5]	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  Fig.	  1	  -­‐	  Cancer	  death	  rate	  in	  the	  US,	  1930-­‐2008.	  This	  figure	  is	  adapted	  from	  ref.	  [4]	  Copyright	  2012,	  American	  Cancer	  Society	  Inc.	  	  
1.2 Cancer	  Therapy	  It	   is	   obvious	   that	   humanity	   has	   long	   been	   baffled	   by	   cancer	   as	   the	   famous	   Greek	  physician	  Galen	  once	  described	  cancer	  to	  be	  incurable.	  To	  this	  day,	  surgery	  remains	  one	  of	  the	  most	  effective	  treatments	  against	  cancer.	  Ideally,	  complete	  excision	  of	  the	  cancer	  cells	  by	   surgery	   would	   cure	   the	   disease.	   However,	   surgery	   alone	   is	   often	   inadequate	   due	   to	  microscopic	  metastasis.	   Furthermore,	   depending	   on	  patient’s	   physical	   condition,	   surgical	  procedures	   may	   sometimes	   cause	   more	   harm	   than	   benefit.	   Therefore,	   less	   invasive	  methods	  such	  as	  radiation	  therapy	  and	  chemotherapy	  are	  often	  applied	  in	  conjunction	  with	  surgical	  procedures.	  [6]	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When	   X-­‐Ray	   was	   first	   discovered	   in	   1896	   by	   Roentgen,	   its	   unique	   imaging	   property	  provided	   the	  medical	   community	  with	   a	   brand	   new	   diagnostic	   tool.	   [7]	   Soon	   after	   X-­‐Ray	  became	   widely	   available,	   researchers	   started	   to	   notice	   inflammation	   and	   minor	   tissue	  damage	  after	  prolonged	  exposures.	  Researchers	  then	  began	  to	  use	  radiation	  to	  treat	  many	  different	   diseases,	   and	   one	   of	   the	   very	   first	   attempts	   for	   radiation	   therapy	   was	   against	  cancer.	   [8]	  Radiation	   therapy	  works	  by	  damaging	   the	  genetic	  DNA	   in	  cancer	  cells	   through	  ionization;	  the	  damage	  can	  be	  either	  direct	  or	  indirect	  ionization.	  For	  direct	  ionization,	  the	  radiation	  directly	  targets	  the	  DNA	  molecules.	  On	  the	  other	  hand,	  indirect	  ionization	  targets	  water	  molecules,	  which	  then	  form	  free	  radicals	  to	  ionize	  DNA	  and	  corrupt	  its	  integrity.	   [9]	  With	   such	   vigorous	   mechanism	   of	   action,	   it	   is	   not	   surprising	   that	   radiation	   affects	   the	  cancer	  cells	  as	  well	  as	  the	  normal	  cells.	  	  	  1.2.1 	  Chemotherapy	  Aside	  from	  radiation	  therapy,	  the	  other	  common	  non-­‐invasive	  treatment	  for	  cancer	  is	  chemotherapy.	  Chemotherapy	  utilizes	  cytotoxic	  chemical	  compounds	   to	  either	  destroy	  or	  restrain	   tumor	   growth.	   [10]	   Unlike	   surgery	   and	   radiation	   therapy,	   chemotherapy	   is	  relatively	  contemporary.	  During	  the	  First	  and	  Second	  World	  War,	  countries	  have	  deployed	  various	   chemical	   weapons	   on	   the	   battlefield,	   one	   of	   which	   was	   mustard	   gas.	   Scientists	  noticed	  that	  the	  victims	  exposed	  to	  mustard	  gas	  have	  significant	  reduction	  in	  white	  blood	  cell	  counts.	  They	  deduced	  that	  the	  chemical	  agent	  has	  the	  ability	  to	  target	  rapidly	  dividing	  cells	   such	   as	   white	   blood	   cells.	   Since	   uncontrolled	   growth	   is	   a	   major	   cancer	   trait,	   they	  rationalized	  that	  the	  chemical	  agent	  has	  the	  potential	  to	  suppress	  cancer	  cells.	  A	  compound	  similar	   to	   mustard	   gas,	   named	   nitrogen	   mustard	   was	   studied	   and	   found	   to	   be	   potent	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against	   certain	   types	   of	   lymphoma.	   [11]	   Nitrogen	   mustard	   was	   the	   first	   of	   a	   group	   of	  chemotherapeutics	   called	   alkylating	   agents.	   Alkylating	   agents	   work	   by	   alkylating	   one	  strand	  of	  DNA	  or	  crosslinking	  two	  strands	  of	  DNA	  (Fig.	  2).	  The	  formation	  of	  covalent	  bonds	  prevents	  DNA	  from	  replication,	  transcription,	  and	  will	  eventually	  lead	  to	  cell	  apoptosis.	  [12]	  Aside	   from	   alkylating	   agents,	   there	   are	   four	   other	   main	   classes	   of	   chemotherapeutics,	  namely	   antimetabolites,	   cytotoxic	   antibiotics,	   mitotic	   inhibitors,	   and	   topoisomerase	  inhibitors.	   [13]	  Each	  of	  these	  classes	  attacks	  cancer	  cells	  with	  a	  different	  mechanism.	  Some	  mimic	  DNA	  building	  blocks	  (Fig.	  3),	  some	  target	  DNA	  directly,	  while	  others	  interfere	  with	  proteins	  that	  are	  essential	  for	  cellular	  replication.	  [14]	  As	  diverse	  as	  chemotherapeutics	  may	  be,	  they	  do	  share	  some	  similarities.	  For	  instance,	  most	  of	  the	  compounds	  target	  constantly	  dividing	   cells.	   [15];	   therefore,	   hair	   follicles	   and	   digestive	   tract	   lining	   cells	   are	   usually	  damaged	  during	  chemotherapy,	   leading	   to	   the	  common	  side	  effects	  often	  associated	  with	  the	  treatment	  such	  as	  hair	  loss	  and	  loss	  of	  appetite.	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  Fig.	  2	  –	  DNA	  alkylating	  agent	  mechanism	  of	  action.	  This	  figure	  is	  adapted	  from	  ref.	  [16].	  Copyright	  2013,	  Elsevier	  B.V.	  	  The	  major	  advantage	  of	   chemotherapy	   is	   that	  drug	  molecules	  are	  small	  and	   they	  are	  distributed	   throughout	   the	   vascular	   system.	   Therefore,	   unlike	   surgery	   and	   radiation	  therapy	  where	   the	   treatments	   are	   localized,	   chemotherapy	   is	   highly	  dispersed	   and	  more	  effective	  against	  microscopic	  metastasis.	  However,	   the	  high	  penetrating	  ability	  acts	   like	  a	  double-­‐edged	   sword.	   Cytotoxic	   drug	   molecules	   can	   reach	   cancer	   cells	   as	   well	   as	   other	  normal	   cells.	   Since	   cytotoxicity	   is	   non-­‐discriminatory,	   chemotherapy	   often	   causes	   many	  adverse	   effects.	   [17]	   To	   alleviate	   chemotherapeutics’	   non-­‐specific	   targeting	   ability,	   a	   new	  modality	  of	  treatment	  called	  targeted	  therapy	  has	  gained	  much	  attention.	  Targeted	  therapy	  utilizes	  drugs	  or	  other	  substances	  such	  as	  antibodies	  to	  identify	  and	  attack	  specific	  types	  of	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cancer	   cells.	   [18]	   With	   the	   ability	   to	   distinguish	   cancer	   cells	   from	   normal	   cells,	   targeted	  therapy	   is	   expected	   to	   be	   more	   effective	   and	   less	   harmful	   to	   non-­‐targeted	   cells.	   One	  example	  of	  targeted	  therapy	  is	  called	  antibody-­‐drug	  conjugates	  (ADCs).	  ADCs	  are	  made	  of	  three	   major	   components,	   a	   targeting	   antibody,	   a	   chemically	   stable	   linker,	   and	   an	   anti-­‐cancer	  drug.	  [19]	  The	  antibody	  will	  guide	  ADCs	  toward	  specific	  tumor	  marker	  and	  will	  then	  trigger	  internalization	  of	  the	  drug	  complex.	  After	  internalization,	  the	  cytotoxic	  drug	  is	  then	  released	  and	  kills	  cancer	  cells.	  With	   two	  ADCs	  already	  available	  on	   the	  market	  and	  more	  than	  thirty	  under	  clinical	  trial,	  it	  is	  not	  hard	  to	  see	  that	  selectivity	  will	  play	  a	  crucial	  role	  in	  the	  future	  of	  molecular	  anti-­‐cancer	  medicine.	  [20]	  	  
	  Fig.	  3	  -­‐	  Antimetabolites	  mimicking	  DNA	  building	  block	  nucleotide.	  This	  figure	  is	  adapted	  from	  ref.	  [21].	  Copyright	  2000,	  Elsevier	  B.V.	  	  
1.3 Targeted	  Drug	  Delivery	  Drug	  delivery	   is	   the	  process	  of	  administering	  pharmaceutical	  agents	   into	   the	  body	  to	  achieve	   therapeutic	   effects.	   Studies	   have	   shown	   that	   sustained	   and	   controlled	   release	   of	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therapeutics	   can	   not	   only	   greatly	   enhance	   their	   efficacy,	   but	   also	   reduce	   non-­‐specific	  cytotoxicity.	   [22]	  Recently,	  pharmaceutical	  companies	  are	  starting	  to	  emphasize	  innovating	  new	  delivery	  technology.	  Compared	  to	  the	  cost	  of	  developing	  a	  new	  therapeutic	  molecule,	  improving	  the	  efficacy	  of	  the	  existing	  drug	  serves	  as	  a	  more	  economical	  alternative.	  	  Among	  these	  developments,	  a	  specific	  category	  called	  targeted	  drug	  delivery	  has	  been	  the	   center	   of	   research.	   [23]	   The	   concept	   of	   targeted	   drug	   delivery	   is	   to	   increase	   the	  therapeutic	   concentration	   exclusively	   at	   select	   part	   of	   the	   body.	   The	   selectivity	   and	  localization	  restricts	  drugs	   from	  accessing	  non-­‐targeted	  normal	  cells,	  and	  thus	  minimizes	  toxic	   effects.	   [24,25]	   It	   is	   important	   to	   note	   here	   that	   targeted	   drug	   delivery	   is	   not	   to	   be	  confused	   with	   targeted	   therapy.	   For	   targeted	   therapy,	   the	   drugs	   themselves	   can	   target	  specific	  molecular	  markers,	  whereas	  for	  targeted	  delivery,	  the	  bioactive	  drugs	  possess	  no	  specificity.	  Instead,	  the	  payloads	  are	  contained	  within	  the	  specially	  engineered	  vehicles	  and	  the	  vehicles	  are	  selective.	  	  Another	  important	  aspect	  for	  targeted	  delivery	  is	  prolonging	  the	  circulation	  time	  in	  the	  blood	   stream	  by	   avoiding	   the	  mononuclear	   phagocyte	   system	   (MPS)	   clearance.	   The	  MPS	  consists	   of	   the	   phagocytic	   cells	   such	   as	  monocytes	   and	  macrophages,	   and	   is	   part	   of	   the	  immune	  system.	  [26]	  The	  primary	  function	  of	  the	  MPS	  is	  to	  destroy	  harmful	  microorganisms	  and	  foreign	  substances.	  Studies	  have	  shown	  that	  the	  phagocytic	  cells	  in	  the	  spleen	  and	  liver	  can	  rapidly	  retain	  the	  majority	  of	  the	  administered	  agents.	  [27]	  Since	  the	  clearance	  process	  is	  mostly	   dependent	   on	   vehicle	   size	   and	   surface	   property,	   to	   evade	   this	   uptake,	   an	   ideal	  vehicle	  should	  be	  less	  than	  100nm	  in	  size	  and	  should	  have	  a	  slightly	  hydrophilic	  surface.	  [28]	  With	  a	  longer	  circulation	  time,	  the	  vehicles	  have	  a	  higher	  ability	  to	  target	  the	  site	  of	  interest.	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1.3.1 Targeting	  Method	  There	  are	  two	  main	  types	  of	  targeting	  methods,	  passive	  targeting	  and	  active	  targeting.	  Passive	   targeting	   refers	   to	   the	   accumulation	   of	   drugs	   at	   a	   particular	   site.	   An	   example	   of	  passive	   targeting	   is	   the	  enhanced	  permeability	  and	   retention	   (EPR)	  effect.	   [29,30]	  The	  EPR	  effect	  refers	  to	  the	  phenomenon	  that	  molecules	  in	  the	  nanometer	  range	  have	  a	  tendency	  to	  accumulate	   near	   cancerous	   tissues	   rather	   than	   normal	   tissues.	   As	  mentioned	  previously,	  one	   of	   the	   hallmarks	   of	   cancer	   is	   continuous	   angiogenesis	   to	   support	   the	   rapid	   tumor	  expansion.	  This	  irregular	  angiogenesis	  results	  in	  defective	  local	  vasculatures	  that	  are	  leaky	  to	   particles	   below	   a	   certain	   size.	   [31]	   (Fig.	   4).	   The	   EPR	   effect	   is	   critical	   important	   for	   a	  delivery	  system	  designed	  to	  target	  cancer.	  	  	  
	  Fig.	  4	  –	  Enhanced	  permeability	  and	  retention	  effect.	  This	  figure	  is	  adapted	  from	  ref.	  [32].	  Copyright	  2010,	  SAGE	  Publications.	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As	   for	   active	   targeting,	   the	   delivery	   system	   is	   modified	   with	   active	   agents	   having	  selective	  affinity	   towards	  biomarkers.	   [33-­‐35]	  Active	   targeting	  can	  be	   further	  classified	   into	  three	  different	  levels.	  First	  order	  targeting,	  or	  organ	  targeting,	  is	  when	  the	  delivery	  system	  releases	   the	   payload	   in	   a	   specific	   organ.	   Second	   order	   targeting,	   or	   cellular	   targeting,	   is	  when	  the	  drug	  is	  released	  to	  the	  particular	  tissues	  or	  cells.	  Lastly,	  third	  order	  targeting,	  or	  subcellular	  targeting,	  is	  when	  the	  system	  can	  deliver	  the	  drug	  to	  the	  intracellular	  site	  of	  the	  specific	  cells.	  [36]	  With	  increasing	  order,	  targeting	  specificity	  increases	  as	  well	  as	  the	  level	  of	  sophistication	   needed.	   Ideally,	   an	   anti-­‐cancer	   targeting	   vehicle	   should	   achieve	   cellular	  targeting,	  if	  not	  subcellular	  targeting.	  The	  active	  agents	  responsible	  for	  targeting	  are	  called	  homing	   devices.	   These	   homing	   devices	   are	   often	   part	   of	   a	   pair	   of	  molecules	   that	   have	   a	  strong	   affinity	   for	   each	   other.	   Interactions	   such	   as	   lectin–carbohydrate,	   ligand-­‐receptor,	  and	  antigen-­‐antibody	  are	  most	  commonly	  used.	  [37]	  	  Other	   than	   the	   homing	   devices	   mentioned	   previously,	   there	   is	   another	   type	   of	  molecules	  called	  aptamers	  that	  have	  attracted	  much	  attention	   in	  the	  past	  25	  years	  and	   is	  praised	   as	   the	   future	   of	   affinity	   molecules.	   [38]	   Aptamers	   are	   pieces	   of	   oligonucleotides	  obtained	   through	   systematic	   evolution	   of	   ligands	   by	   exponential	   enrichment	   (SELEX)	  process	  (Fig.	  5).	  SELEX	  is	  a	  technique	  for	  producing	  single-­‐stranded	  oligonucleotides	  with	  affinity	  toward	  a	  specific	  ligand.	  In	  a	  typical	  SELEX	  cycle,	  an	  initial	  oligonucleotide	  library	  is	  generated	   with	   fixed-­‐length	   random	   region	   flanked	   by	   conserved	   3’	   and	   5’	   ends.	   The	  random	  sequences	  are	  exposed	   to	   the	   target	   ligand	  and	   the	  ones	   that	  do	  not	  bind	   to	   the	  target	   are	   removed.	   Binding	   sequences	   are	   then	   eluted	   and	   amplified	   for	   subsequent	  rounds	  of	  selection.	  After	  approximately	  ten	  to	  fifteen	  cycles,	  the	  remaining	  sequences	  are	  cloned	  and	  sequenced.	  Prior	  to	  aptamers,	  antibodies	  have	  been	  the	  gold	  standard	  of	  affinity	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agents.	  However,	  its	  large	  size	  and	  instability	  has	  always	  been	  a	  major	  drawback.	  Aptamers’	  reputation	   stemmed	   from	   their	   strong	   affinities	   comparable	   to	   that	   of	   antibodies.	   Since	  aptamers	   are	   oligonucleotides,	   they	   can	  withstand	   a	  much	   harsher	   temperature	   and	   pH	  than	  antibodies	  do.	  [39,40]	  Unlike	  antibody	  production,	  aptamers	  are	  chemically	  synthesized	  and	  thus	  have	  miniscule	  batch-­‐to-­‐batch	  difference.	  With	  so	  many	  improvements	  and	  great	  flexibility	  for	  modification	  and	  coupling,	  countless	  studies	  have	  been	  done	  using	  aptamers	  as	  the	  homing	  agents.	  [41-­‐43]	  	  
	  Fig.	  5	  –	  The	  SELEX	  system	  cycle.	  This	  figure	  is	  adapted	  from	  ref.	  [44].	  Copyright	  2015,	  Elsevier	  B.V.	  	  
1.4 Nanoparticle	  Delivery	  System	  Designing	   a	   delivery	   system	   involves	   many	   complications	   such	   as	   toxicity,	   stability,	  biocompatibility,	  biodegradability,	  and	  cost	  effectiveness.	  [45]	  To	  take	  it	  one	  step	  further,	  a	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targeted	  delivery	  system	  is	  even	  more	  complex	  and	  requires	  higher	  sophistication.	  On	  top	  of	   all	   the	   requirements,	   an	   ideal	   targeted	   delivery	   system	   also	   needs	   to	   restrict	   drug	  distribution	   to	   only	   the	   target	   location.	   In	   terms	  of	   anti-­‐cancer	   targeted	  delivery	   system,	  one	  of	  the	  most	  actively	  researched	  topics	  is	  nanoparticles.	  As	  a	  targeted	  delivery	  system,	  nanoparticles	   possess	   many	   unique	   advantages.	   For	   starters,	   nanoparticles	   in	   the	   size	  range	  of	  10-­‐100nm	  can	   simultaneously	   take	  advantage	  of	   the	  EPR	  effect	   and	  avoid	   renal	  clearance.	  [46]	  By	  fine-­‐tuning	  their	  surface	  properties,	  nanoparticles	  can	  avoid	  macrophage	  uptake	  and	  have	  high	  tumor	  penetration.	  Nanoparticles’	  high	  surface	  area	  is	  also	  capable	  of	  accommodating	  multiple	  targeting	  agents,	  which	  can	  allow	  multi-­‐valent	  binding	  to	  further	  increase	  affinity.	  [47]	  Lastly,	  nanoparticles	  have	  a	  large	  payload	  capacity,	  capable	  of	  carrying	  multiple	  types	  of	  drugs	  and	  can	  protect	  therapeutics	  from	  potential	  degradation.	  [48]	  	  With	  more	  than	  ten	  commercialized	  drugs	  on	  the	  market,	  liposome-­‐based	  systems	  are	  currently	   the	  most	   common	  nanoparticle	   delivery	   system.	   [49,50]	   Liposomes	   are	   synthetic	  vesicles	  composed	  of	  at	  least	  one	  lipid	  bilayer.	  Liposome’s	  success	  can	  be	  attributed	  to	  its	  attractive	  biological	  properties	   such	  as	  high	  biocompatibility	  and	   low	   toxicity.	   Its	   surface	  property	  and	  size	  can	  be	  easily	  manipulated.	  And	  most	  importantly,	  liposomes	  are	  capable	  of	  accommodating	  both	  hydrophilic	  and	  hydrophobic	  drugs.	  [51]	  Clinical	  studies	  have	  shown	  improved	  efficacy	  and	  reduced	  cytotoxicity	  for	  liposome-­‐enclosed	  chemotherapeutics	  such	  as	   doxorubicin.	   [52]	   However,	   one	   major	   flaw	   for	   liposomes	   is	   its	   susceptibility	   to	   MPS	  clearance	   and	   therefore	   short	   circulation	   time.	   [53]	   A	   number	   of	   solutions	   have	   been	  proposed	   including	  masking	   the	   particle	   with	   polyethylene	   glycol	   (PEG).	   [54]	   Apart	   from	  liposome	   systems,	   the	   FDA	   also	   approved	   a	   few	   other	   types	   of	   nanoparticles	   such	   as	  protein	   nanoparticles	   and	   polymeric	  micelles.	   [55,56]	   Each	   type	   of	   nanoparticles	   has	   their	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own	  unique	  strengths	  and	  weaknesses,	  and	  recently	  more	  attention	  are	  started	  to	  focus	  on	  using	  biodegradable	  materials	  for	  drug	  delivery.	  	  	  
1.5 Structure	  and	  Chemistry	  of	  Starch	  Before	   any	   further	   discussion	   about	   biodegradable	   nanoparticles,	   it	   is	   important	   to	  take	   an	   in-­‐depth	   look	   into	   starch,	   as	   it	   is	   the	  material	   of	   choice	   for	   this	   thesis.	   Starch	   is	  synthesized	  by	  most	  plants	  as	  energy	  storage,	  and	  is	  one	  of	  the	  most	  abundant	  materials	  on	  Earth.	  As	  a	  biodegradable,	  non-­‐toxic,	  and	  cheap	  biopolymer,	  starch	  has	  a	  wide	  spectrum	  of	  applications.	  Pharmaceutical	  companies	  use	  starch	  as	  drug	  tablet	  filler;	  food	  companies	  use	  starch	  film	  as	  barrier	  for	  packaging;	  and	  paper	  companies	  uses	  cooked	  starch	  as	  coating	  for	  desirable	  properties.	  [57]	  Extensive	  research	  has	  been	  done	  to	  analyse	  starch’s	  composition	  and	   structure	  but	   it	   is	   only	  until	   the	   last	   decade	  do	  we	  have	   a	  more	   accurate	   concept	  of	  starch’s	  chemistry.	  
	  Fig.	  6	  –	  Structures	  of	  amylose	  and	  amylopectin.	  This	  figure	  is	  adapted	  from	  ref.	  [58].	  Copyright	  2002,	  Elsevier	  B.V.	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The	  basic	  macrostructure	  of	  starch	  is	  a	  starch	  granule.	  A	  starch	  granule	  is	  composed	  of	  two	  similar	  macromolecules	  made	  with	  α-­‐glucose	  building	  block,	  amylose	  and	  amylopectin	  (Fig.	  6).	  Amylose	  is	  a	  linear	  polymer	  of	  glucose	  units	  connected	  with	  mostly	  α	  (1,	  4)	  bonds	  and	   some	   α	   (1,	   6)	   branching.	   Compared	   to	   amylopectin,	   the	   highly	   linear	   amylose	   has	  relatively	  low	  molecular	  weight	  of	  around	  1	  x	  106.	  On	  the	  other	  hand,	  amylopectin	  is	  highly	  branched	   with	   one	   α	   (1,	   6)	   branching	   per	   22	   glucose	   units.	   The	   heavily	   branched	  amylopectin	  structure	  has	  much	  larger	  molecular	  weight	  of	  1	  ×	  108.	  Starch	  granules	  from	  different	   botanical	   sources	   have	  different	   ratio	   of	   amylose	   to	   amylopectin,	   and	   therefore	  different	  characteristic.	  Another	  important	  property	  about	  amylose	  and	  amylopectin	  is	  that	  the	   polymeric	   chains	   can	   form	   double	   helices	   and	   may	   be	   partially	   crystalized.	   [59]	   The	  crystalline	   may	   be	   either	   A-­‐type	   where	   the	   helices	   are	   tightly	   packed	   with	   less	   water	  molecules,	   or	   B-­‐type	   with	   a	   more	   open	   structure	   and	   a	   hydrated	   core	   (Fig.	   7).	   Recent	  findings	  also	  suggest	  a	  C-­‐type	  structure	  that	  is	  a	  combination	  of	  both	  A-­‐	  and	  B-­‐type.	  	  	  
	  Fig.	  7	  –	  A-­‐	  and	  B-­‐type	  starch	  crystalline.	  This	  figure	  is	  adapted	  from	  ref.	  [59].	  Copyright	  2004,	  Elsevier	  B.V.	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Due	   to	   the	   great	   complexity	   of	   starch	   structure,	   a	   universally	   accepted	  model	   is	   still	  lacking.	  However,	  one	  prevailing	  model	   is	  a	  multi-­‐scale	  structure	  subdividing	  starch	  from	  granule	   to	   the	   two	   α-­‐glucan.	   [60]	   (Fig.	   8).	   Starch	   granule	   is	  made	   of	   alternating	   layers	   of	  amorphous	  growth	  rings	  and	  semicrystalline	  growth	  rings.	  The	  semicrystalline	  growth	  ring	  is	   packed	   with	   special	   sub-­‐units	   called	   blocklets.	   Blocklets	   are	   20~50nm	   in	   length	   and	  constitutes	  of	  alternating	  stacks	  amorphous	  and	  crystalline	  lamellae.	  The	  crystalline	  region	  is	   made	   of	   tightly	   packed	   amylopectin	   double	   helices,	   whereas	   the	   amorphous	   lamellae	  correspond	  to	  the	  branching	  point	  of	  amylopectin.	  On	  the	  other	  hand,	  amylose	  is	  randomly	  distributed	  in	  both	  the	  amorphous	  and	  crystalline	  region.	  	  	  
	  Fig.	  8	  –	  Starch	  multi-­‐scale	  structure.	  This	  figure	  is	  adapted	  from	  ref.	  [61].	  Copyright	  2010,	  American	  Chemical	  Society	  Publications.	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1.6 Polysaccharides	  Delivery	  System	  Biodegradable	  nanoparticles	  are	  sub-­‐micron	  particles	  typically	  with	  size	  below	  100nm.	  Aside	   from	   the	   previously	   mentioned	   advantages	   of	   a	   nanoparticle	   delivery	   system,	   its	  biodegradability	   also	   provides	   the	   carrier	   with	   controlled	   release	   potential.	   [62]	   Many	  polymeric	  materials	  such	  as	  polylactic	  acid,	  polyglycolic	  acid,	  proteins,	  and	  polysaccharides	  have	  been	  explored	  for	  drug	  delivery	  application.	  Among	  these	  materials,	  polysaccharides	  have	  gained	  increasing	  attention	  with	  their	  outstanding	  properties.	  As	  natural	  biopolymers,	  polysaccharides	   are	   non-­‐toxic	   and	   readily	   biodegradable.	   [63,64]	   They	   can	   be	   found	   in	   a	  variety	  of	  plants	  and	  animals	  with	  a	  wide	  range	  of	  molecular	  weights.	   [65]	  Polysaccharides	  such	  as	  cellulose,	  chitosan,	  and	  alginate	  are	  among	  the	  most	  abundant	  biomass.	  Extraction	  and	  processing	  of	  polysaccharides	  have	   relatively	   low	  cost.	  From	  a	  chemical	  perspective,	  polysaccharides	   have	   many	   reactive	   groups	   and	   can	   be	   easily	   modified	   for	   desirable	  properties.	  Furthermore,	  many	  polysaccharides	  have	  hydrophilic	  functional	  groups	  such	  as	  hydroxyl,	   amino,	   and	   carboxyl,	  which	   favour	   the	   formation	   of	   non-­‐covalent	   binding	  with	  biological	  tissues.	  [65]	  The	  bio-­‐adhesion	  property	  can	  often	  increase	  drug	  residence	  time.	  Some	   of	   the	   earliest	   studies	   on	   polysaccharide	   nanoparticles	  were	   done	   on	   chitosan	  due	  to	  its	  strong	  bio-­‐adhesion.	  Particles	  were	  first	  prepared	  through	  covalent	  crosslinking.	  However,	  subsequent	  studies	  exposed	  the	  toxicity	  of	  crosslinkers	  and	  suggested	  alternative	  crosslinking	  mechanisms	  such	  as	  ionic	  crosslinking	  with	  charged	  ions.	  [66]	  Another	  popular	  particle	   synthesis	  method	   is	  modifying	   polysaccharides	  with	   hydrophobic	   chains;	   so	   the	  amphiphilic	   copolymers	   can	   self-­‐aggregate	   in	   aqueous	   conditions	   to	   form	   nanoparticles.	  Other	  than	  chitosan,	  cellulose	  is	  also	  under	  active	  research	  for	  its	  delivery	  potential.	  Similar	  to	   starch,	   cellulose	   is	   also	  made	  of	   glucose	   and	   contains	  both	   amorphous	   and	   crystalline	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regions.	  A	   common	  method	  of	  preparing	  cellulose	  nanoparticles	   is	   to	   subject	   cellulose	   to	  acid	   hydrolysis	   to	   remove	   the	   amorphous	   region.	   [67]	   The	   resulting	   elongated	   particles	  specifically	   known	   as	   cellulose	   nanocrystals	   have	   proven	   to	   be	   non-­‐toxic	   and	   capable	   of	  delaying	  MPS	  clearance.	  [67]	  	  	  1.6.1 General	  Methods	  for	  Starch	  Nanoparticle	  Preparation	  	  Compared	   to	   other	   polysaccharides,	   there	   are	   fewer	   studies	   on	   starch	   nanoparticles	  (SNPs)	   and	   their	   applications.	   [68,69]	   The	   SNP	   preparation	  methods	   can	   be	   classified	   into	  either	  a	  top-­‐down	  or	  a	  bottom-­‐up	  process.	  Top-­‐down	  process	  refers	  to	  breaking	  down	  of	  larger	   starch	  particles	   such	   as	   granules	   or	  micron	   size	   starch,	   into	   nanoparticles.	  On	   the	  other	   hand,	   bottom-­‐up	   process	   describes	   the	   build-­‐up	   of	   smaller	   molecules	   into	   larger	  macromolecules.	   Examples	   of	   bottom-­‐up	   processes	   are	   self-­‐assembling	   and	   nano-­‐precipitation.	   [70-­‐72]	  Most	  of	   the	  current	   literature	   follows	   the	   top-­‐down	  process	  since	   the	  starch	  granule	  is	  the	  most	  readily	  accessible	  starting	  material.	  	  As	  mentioned	  before,	  starch	  shares	  similar	  chemical	  structure	  with	  cellulose	  and	  they	  both	  have	  crystalline	  and	  amorphous	  region.	  Therefore,	  just	  like	  cellulose,	  acid	  hydrolysis	  is	  one	  of	  the	  most	  common	  methods	  of	  preparing	  SNPs.	  [73]	  Studies	  have	  shown	  most	  starch	  hydrolysis	  occur	  in	  a	  two-­‐stage	  process.	  The	  initial	  rapid	  hydrolysis	  stage	  can	  be	  attributed	  to	   the	   disintegration	   of	   the	   amorphous	   region.	   The	   subsequent	   break	   down	   of	   the	  crystalline	   region	   is	   significantly	   retarded	   by	   the	   densely	   packed	   helices.	   A	   milder	  preparation	  process	  for	  SNPs	  is	  enzymatic	  degradation.	  A	  handful	  of	  studies	  have	  recorded	  using	  α-­‐amylase	   to	  breakdown	  starch	   into	  submicron	   fragments.	   [74]	  However,	  one	  major	  flaw	   with	   enzymatic	   treatment	   is	   that	   the	   resulting	   starch	   particles	   have	   broad	   a	   size	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distribution.	   Aside	   from	   chemical	   processes,	   different	   physical	   treatments	   such	   as	  ultrasonication,	   extrusion,	   and	   high-­‐pressure	   homogenization	   have	   also	   been	   used	   to	  breakdown	  starch	  granules	  into	  SNPs.	  [75,76]	  Since	  breaking	  down	  granule	  into	  nanoparticle	  is	  heavily	  affected	  by	  the	  source,	  pH,	  temperature	  and	  the	  amount	  and	  type	  of	  crosslinking	  agent,	  the	  lab	  scale	  produced	  starch	  nanoparticles	  often	  suffer	  from	  large	  batch-­‐to-­‐batche	  variation.	   In	   this	   thesis,	   we	   aim	   to	   test	   a	   starch	   nanoparticle	   that	   is	   produced	   in	   an	  industrial	  scale.	  	  	  1.6.2 EcoSphereTM	  Currently	   there	   are	   only	   a	   couple	   of	   industrial	   applications	   for	   SNPs.	   EcoSphereTM	  produced	  by	  EcoSynthetix	   Inc.	   is	  one	  of	   the	   commercially	  available	  SNPs.	  EcoSphereTM	   is	  marketed	  as	  a	  bio-­‐based	  latex	  in	  substitution	  of	  petroleum-­‐based	  binder	  and	  paper	  coating.	  EcoSphereTM	  has	  been	  proven	  to	  have	  superior	  quality	  over	  synthetic	  latex	  and	  much	  more	  environmental	   friendly.	   [77]	   The	   particles	   are	   prepared	   through	   a	   patented	   reactive	  extrusion	   process	   capable	   of	   simultaneously	   extruding	   and	   crosslinking.	   [77,78]	   Starch	  premix	  and	  plasticizer	  glycerol	   are	   fed	   simultaneously	   into	   the	   twin-­‐screw	  extruder.	  The	  extrusion	   process	   exposed	   starch	   to	   high	   pressure	   and	   temperature.	   [79]	   The	   vigorous	  condition	  destroys	  starch’s	  crystalline	  region	  and	  completely	  gelatinized.	  With	  the	  addition	  of	   crosslinker,	   the	   α-­‐glucan	   chains	   can	   be	   crosslinked.	   And	   by	   adjusting	   the	   amount	   of	  crosslinker,	  the	  resulting	  SNPs’	  size	  and	  properties	  can	  be	  controlled.	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  Fig.	  9	  –	  Glyoxal	  crosslinking	  mechanism,	  R-­‐OH	  represents	  the	  hydroxyl	  group	  on	  glucose.	  [80]	  	  The	  crosslinker	  used	  to	  prepare	  EcoSphereTM	  nanoparticles	  (ENPs)	  is	  glyoxal.	  Glyoxal	  can	   crosslink	   the	   α-­‐glucan	   chains	   by	   forming	   either	   hemiacetal	   or	   acetal	   group	  with	   the	  hydroxyl	  on	  the	  glucose	  units	  (Fig.	  9).	  Data	  suggest	  higher	  crosslinker	  concentration	  would	  result	   in	  smaller	  ENPs.	  Fundamental	  studies	  conducted	  by	  EcoSynthetix	   Inc.	  also	  observe	  swelling	  behaviour	  when	  ENPs	  are	  dispersed	  in	  an	  aqueous	  solvent	  (Fig.	  10).	  This	  unique	  property	   is	   favourable	   for	   drug	   delivery	   since	   previous	   studies	   suggest	   that	   the	   drug	  loading	  efficiency	  is	  correlated	  to	  the	  degree	  of	  swelling.	  [81]	  	  
	  Fig.	  10	  –	  EcoSphereTM	  nanoparticle	  swollen	  structure.	  This	  figure	  is	  adapted	  from	  ref.	  [81].	  Copyright	  2004,	  Elsevier	  B.V.	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1.7 Thesis	  Objective	  The	   objective	   of	   this	   research	   is	   to	   develop	   an	   ENP-­‐based	   drug	   delivery	   vehicle,	  specifically	   for	   anti-­‐cancer	   purposes.	   As	   a	   starch-­‐based	   material,	   EcoSphereTM	   has	   high	  biocompatibility,	   good	   biodegradability,	   and	   is	   cheap	   to	   produce.	   Furthermore,	   as	   a	  nanoparticle	   of	   size	   below	   100	   nm,	   EcoSphereTM	   takes	   advantage	   of	   the	   EPR	   effect	   and	  facilitates	  local	  accumulation	  in	  tumors.	  Therefore,	  ENPs	  serve	  as	  an	  excellent	  platform	  for	  anti-­‐cancer	  drug	  delivery.	  To	  further	  strengthen	  ENPs’	  capabilities,	  a	  homing	  device	  will	  be	  modified	  onto	   the	  nanoparticles.	  To	  be	  more	  specific,	   aptamers	  will	  be	  used	   to	  guide	   the	  vehicle	  toward	  targeting	  the	  right	  cells.	  The	  modification	  strategy	  involves	  two	  main	  steps,	  oxidation	   and	   aptamer	   conjugation	   (Fig.	   11).	   ENPs	   will	   be	   first	   subject	   to	   (2,2,6,6,-­‐tetramethylpiperidin-­‐1-­‐yl)oxy	   (TEMPO)-­‐mediated	   oxidation	   to	   convert	   its	   C6	   hydroxyl	  group	   into	   carboxylic	   group.	   After	   partial	   oxidation,	   amine-­‐modified	   aptamers	   are	  conjugated	   onto	   the	   nanoparticles	   through	   1-­‐ethyl-­‐3-­‐(3-­‐dimethylaminopropyl)	  carbodimide	  (EDC)	  and	  N-­‐hydroxysuccinimide	  (NHS)	  coupling.	  After	  the	  modifications,	  the	  resulting	   vehicle	   properties	   such	   as	   cellular	   internalization	   and	   selectivity	   are	   to	   be	  evaluated	  and	  compared	  against	  market	  available	  delivery	  vehicle.	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  Fig.	  11	  –	  Schematic	  for	  ENPs	  modification.	  [82]	  	  The	   two	  modification	   processes	   and	   the	   final	   evaluation	   study	   constituted	   the	   three	  major	   milestones	   of	   this	   thesis,	   and	   therefore	   one	   chapter	   will	   be	   dedicated	   to	   each	  milestone.	  For	  oxidation,	  ENPs	  are	  subject	  to	  different	  levels	  of	  oxidation	  and	  characterized	  with	  spectroscopic	  techniques.	  For	  aptamer	  conjugation,	  gel	  electrophoresis	  will	  be	  used	  to	  quantify	   coupling	   efficiency.	   The	   conjugation	   process	   is	   also	   subject	   to	   optimization	   to	  reduce	  DNA	  loss.	  Finally,	   the	  modified	  vehicle	  will	  be	  evaluated	  using	  microscopy	  and	  be	  compared	  to	  market	  available	  liposomes.	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Chapter	  2.	  Oxidation	  of	  Starch	  Nanoparticles	  Starch	   is	  a	  polymer	  made	  of	  glucose.	  To	  attach	  DNA	  to	  starch	  nanoparticles,	   the	   first	  step	  of	  modification	  is	  to	  selectively	  oxidize	  starch’s	  C6	  hydroxyl	  group	  to	  carboxyl	  group.	  Since	  the	  hydroxyl	  moiety	  is	  less	  reactive,	  oxidizing	  it	  to	  a	  carboxylic	  group	  is	  required	  for	  the	   subsequent	   coupling	   reaction.	   ENPs	   provided	   by	   EcoSynthetix	   Inc.	   are	   subject	   to	   a	  different	   extent	   of	   oxidation	   to	   evaluate	   the	   optimal	   oxidation	   level	   for	   the	   subsequent	  conjugation.	   To	   confirm	   oxidation	   process,	   spectroscopic	  measurements	   such	   as	   nuclear	  magnetic	  resonance	  (NMR)	  spectra	  were	  collected.	  Particle	  colloidal	  properties	  such	  as	  size	  and	   ζ-­‐potential	   were	   also	   measured	   using	   dynamic	   light	   scattering	   (DLS)	   and	   phase	  analysis	  light	  scattering	  (PALS).	  	  	  
2.1	  TEMPO	  Oxidation	  of	  ENPs	  TEMPO-­‐mediated	   is	   a	   racial	   catalyst	   used	   for	   oxidizing	   primary	   alcohols.	   Multiple	  studies	   have	   shown	   TEMPO-­‐mediated	   reaction	   on	   different	   polysaccharides	   resulting	   in	  highly	   selective	   primary	   hydroxyl	   oxidation.	   [83,84]	   In	   the	   case	   of	   starch,	   only	   the	   C6	  hydroxyl	   is	   converted.	   The	   complete	   TEMPO-­‐mediated	   oxidation	   is	   a	   two-­‐step	   process	  (Fig.12).	  The	  primary	  alcohol	  is	  oxidized	  into	  an	  aldehyde	  before	  a	  second	  oxidation	  into	  a	  carboxyl	   group.	   As	   shown	   in	   the	   reaction	  mechanism,	   the	   initial	   hydroxyl	   is	   oxidized	   by	  TEMPO.	  The	  other	  catalyst,	  hypobromite	  helps	  to	  reactivate	  TEMPO	  for	  further	  reactions.	  The	  addition	  of	  sodium	  hypochlorite	  then	  restores	  hypobromite’s	  catalytic	  activity.	  For	  the	  second	   oxidation	   to	   occur,	   the	   resulting	   aldehyde	   first	   forms	   an	   intermediate	   with	  hydroxide	  ions	  before	  further	  oxidation.	  	  To	  completely	  oxidize	  one	  mole	  of	  hydroxyl	  into	  carboxyl,	   two	  moles	   of	   sodium	  hypochlorite	   (NaClO)	   and	   one	  mole	   of	   sodium	  hydroxide	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(NaOH)	  are	  needed.	  Therefore	  by	  calculating	  the	  number	  of	  C6	  hydroxyl	  and	  adjusting	  the	  amount	  of	  NaOH	  added,	  oxidation	  extent	  can	  be	  controlled.	  Since	  the	  optimal	  reaction	  is	  at	  pH	  10-­‐11,	  reaction	  pH	  is	  also	  monitored.	  [85]	  	  	  
	  Fig.	  12	  –	  TEMPO-­‐mediated	  oxidation	  mechanism.	  This	  figure	  is	  adapted	  from	  ref.	  [83].	  Copyright	  2003,	  Elsevier	  B.V.	  	  ENPs	  obtained	   from	  EcoSynthetix	   Inc.	  were	   subject	   to	  TEMPO-­‐mediated	  oxidation	   at	  1%,	  2%,	  5%,	  10%	  and	  20%.	  Dextrin	  is	  the	  product	  of	  starch	  hydrolysis,	  and	  was	  used	  as	  the	  experimental	  control	  and	  oxidized	  to	  2%	  and	  20%.	  After	  oxidation,	  starch	  was	  precipitated	  with	   excess	   ethanol	   and	   lyophilized	   to	   obtain	   powered	   product.	   Prior	   to	   any	  characterization,	   an	   evidence	   of	   oxidation	   can	   be	   observed	   from	   sample’s	   solubility	   in	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water.	   Figure	   13	   shows	   40	   μL	   of	   5%	   (w/w)	   oxidized	   starch	   and	   dextrin	   samples	  precipitated	  with	  excess	  ethanol.	  The	  samples	  were	  oxidized	  to	  different	  extents	  and	  it	   is	  obvious	  that	  samples	  with	  a	  higher	  oxidation	  level	  are	  less	  susceptible	  to	  precipitation.	  The	  oxidation	  process	   introduced	  hydrophilic	   carboxyl	   groups	   to	   starch.	  Therefore	   compared	  to	  the	  others,	  the	  more	  oxidized	  samples	  have	  a	  higher	  solubility	  in	  water	  and	  is	  thus	  more	  easily	  dispersed.	  	  	  
	  Fig.	  13	  –	  Oxidation	  level	  V.S.	  starch	  solubility	  in	  water.	  	  	  
2.2	  Spectroscopic	  Characterization	  To	  further	  confirm	  ENPs’	  oxidation,	  spectroscopic	  measurements	  were	  used.	  	  	  2.2.1	  NMR	  For	  non-­‐oxidized	  starch,	  all	  the	  hydrogen	  are	  attached	  to	  aliphatic	  carbon	  or	  hydroxyl,	  therefore,	  shifts	  on	  proton	  NMR	  should	  all	  be	  below	  6	  ppm.	  And	  as	  previously	  mentioned,	  TEMPO-­‐mediated	  oxidation	   can	  produce	  either	  a	   carboxylic	   group	  or	  an	  aldehyde	  group.	  An	  easy	  indication	  for	  oxidation	  is	  the	  presence	  of	  shifts	  at	  around	  9	  ppm	  for	  the	  aldehyde	  proton.	   Similar	   logic	   can	   be	   applied	   to	   the	   13C	  NMR.	  Non-­‐oxidized	   starch	   has	   exclusively	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alkane	  carbon	  and	  therefore	  all	  shifts	  should	  be	  below	  120	  ppm.	  [86]	  Any	  signal	  above	  160	  ppm	  represents	   the	  carbonyl	   from	  either	  carboxyl	  or	  aldehyde.	  For	  quantitative	  analysis,	  integration	  of	  aldehyde	  shift	  on	  1H	  NMR	  can	  be	  compared	  with	  the	  non-­‐oxidized	  C6	  shift.	  On	   13C	   NMR,	   integration	   of	   both	   carbonyl	   shifts	   from	   aldehyde	   and	   carboxyl	   can	   also	  express	  the	  relative	  oxidation	  extent.	  	  For	   cleaner	   spectrums,	   the	   NMRs	   of	   the	   oxidized	   ENP	   samples	   were	   done	   in	   D2O.	  Therefore	  the	  exchangeable	  proton	  on	  carboxyl	  cannot	  be	  observed.	  What	  is	  observable	  is	  the	  other	  oxidation	  product,	  aldehyde.	  As	  shown	  in	  Fig.	  14,	  oxidation	  can	  be	  confirmed	  with	  the	   aldehyde	   proton	   peak	   at	   around	   9.1	   ppm	   displaying	   increasing	   intensity	   with	  increasing	  oxidation	  level.	  The	  observed	  shift	  intensity	  does	  not	  increase	  linearly	  with	  the	  oxidation	  extent.	  This	  non-­‐linear	  correlation	   is	  due	  to	  the	  two-­‐step	  oxidation	  mechanism.	  Initially,	  oxidation	  will	  produce	  mostly	  aldehyde	  and	  much	  less	  carboxyl,	  but	  as	  oxidation	  continues,	  more	  and	  more	  of	  the	  aldehyde	  will	  be	  converted	  into	  carboxyl.	  Therefore,	  the	  intensity	   of	   the	   aldehyde	   shift	   at	   9	   ppm	  will	   first	   increases,	   then	   plateau	   and	   eventually	  disappears	  as	  the	  oxidation	  level	  increases.	  Interestingly,	  there	  are	  also	  minor	  unidentified	  shifts	  under	  6ppm	  showing	  proportional	  strength	  with	  increasing	  oxidation	  level.	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  Fig.	  14	  –	  1H	  NMR	  spectrums	  of	  oxidized	  ENP	  samples.	  	  
13C	  NMR	  was	  also	  done	   to	  directly	  observe	   carboxyl	   groups.	   Since	   13C	  NMR	   is	  not	   as	  sensitive	  as	  1H	  NMR	  and	  the	  carbonyl	  group	  is	  only	  present	  in	  a	  small	  amount,	  only	  the	  20%	  oxidized	   ENP	   sample	   was	   measured.	   The	   measurement	   was	   left	   over	   night	   to	   obtain	  maximum	  signal	  strength.	  As	  shown	  in	  Fig.	  15,	  the	  majority	  of	  the	  shifts	  are	  below	  120	  ppm	  and	  belongs	  to	  the	  non-­‐oxidized	  starch.	  The	  two	  signals	  observed	  at	  around	  190	  ppm	  and	  175	  ppm	  were	  identified	  to	  be	  the	  aldehyde	  and	  the	  carboxyl	  carbon	  respectively.	  Due	  to	  the	   low	   signal	   to	   noise	   ratio,	   shift	   integration	   and	   quantitative	   analysis	   were	   not	   done.	  However,	  the	  relative	  strength	  of	  the	  two	  carbonyl	  shifts	  and	  the	  ratio	  of	  carbonyl	  shifts	  to	  non-­‐oxidized	  C6	  shifts	  were	  in	  close	  agreement	  with	  the	  literature.	  [80]	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  Fig.	  15	  –	  13C	  NMR	  spectrum	  of	  20%	  oxidized	  ENPs.	  	  2.2.2	  DLS	  and	  Zeta-­‐Potential	  The	  oxidized	  ENP	  size	  and	  ζ-­‐potential	  were	  measured	  using	  DLS	  and	  PALS	  respectively	  at	  three	  different	  pHs.	  Previous	  literatures	  indicate	  that	  unmodified	  ENPs	  are	  under	  50	  nm	  and	  no	  net	  charge	  on	  particle	  surface.	  Since	  TEMPO-­‐mediated	  oxidation	  was	  done	  at	  pH	  10-­‐11,	   some	   depolymerisation	   on	   starch	   chains	   are	   expected.	   Furthermore,	   after	   oxidation,	  carboxylic	  groups	  are	  introduced	  onto	  the	  particles,	  and	  therefore	  the	  surface	  charge	  will	  most	  likely	  be	  affected.	  For	  the	  DLS	  measurements,	  the	  non-­‐oxidized	  ENP	  sample	  size	  stayed	  relatively	  stable	  at	  just	  under	  30	  nm	  for	  all	  three	  pHs	  (Fig.	  16).	  The	  less	  oxidized	  samples,	  namely	  the	  1%,	  2%,	  and	  5%	  showed	  slight	  size	  reduction	  but	  consistent	  throughout	  the	  three	  different	  pHs.	  The	   decreasing	   size	   can	   be	   attributed	   to	   the	   α-­‐1,6-­‐glucosidic	   bond	   cleavage	   during	   the	  oxidation	   process.	   For	   the	   10%	  and	   20%	  oxidized	   samples,	   a	   significant	   increase	   in	   size	  was	  observed	  especially	  at	  pH	  7	  and	  8.	  Size	  measurements	  also	  increased	  at	  pH	  9	  but	  not	  as	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significant.	   The	   size	   increase	   for	   more	   oxidized	   samples	   is	   counterintuitive	   since	  depolymerisation	  were	   expected	   during	   oxidation.	   One	   possible	   explanation	   for	   the	   size	  increase	  is	  hydrogen	  bonding.	  We	  noticed	  bulk	  gel	  formation	  when	  the	  oxidized	  ENPs	  were	  heated.	  The	  gelation	  observed	  was	  reversible	  by	  changing	  the	  oxidized	  ENPs	  concentration	  in	   water.	   After	   partial	   oxidation,	   starch	   chains	   acquire	   carbonyl	   groups	   from	   either	  aldehyde	  or	  carboxyl.	  The	  newly	  introduced	  carbonyls	  can	  interact	  with	  adjacent	  hydroxyls	  to	   form	   hydrogen	   bonds	   and	   possibly	   lead	   to	   aggregation.	   Small	   starch	   fragments	   from	  depolymerisation	  may	   also	   contribute	   to	   aggregation	   by	   exposing	  more	   surface	   area	   for	  hydrogen	  bonding.	  	  	  
	  Fig.	  16	  –	  Size	  measurements	  of	  oxidized	  ENP	  samples	  at	  different	  pHs.	  The	  ENP	  concentration	  was	  1%	  (w/w).	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The	   ζ-­‐potential	   of	   the	   oxidized	   ENPs	   was	   measured	   using	   PALS.	   PALS	   measures	  particle	  ζ-­‐potential	  by	  applying	  an	  electric	  field	  to	  the	  dispersion.	  The	  particles	  then	  move	  with	   a	   velocity	   related	   to	   their	   charge	   and	   the	   velocity	   is	   measured	   to	   calculate	   its	   ζ-­‐potential.	  For	  ζ-­‐potential	  measurements,	  the	  non-­‐oxidized	  ENPs	  have	  charge	  close	  to	  0	  mV.	  This	   result	   is	   in	   close	   agreement	   with	   previous	   findings.	   [87]	   For	   the	   different	   oxidized	  samples,	  as	  the	  oxidation	  levels	  increase,	  the	  particle	  surface	  charge	  displays	  a	  decreasing	  trend.	   This	   phenomenon	   is	   intuitive	   as	   oxidation	   introduces	   negative	   carboxyl	   groups	   to	  starch	  chains,	  resulting	  in	  higher	  oxidation	  and	  more	  negative	  charges.	  	  
	  Fig.	  17	  –	  ζ-­‐potential	  measurements	  of	  oxidized	  ENP	  samples	  at	  different	  pHs.	  The	  ENP	  concentration	  was	  1%	  (w/w).	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2.3	  Materials	  and	  Methods	  2.3.1	  Materials	  ENPs	   with	   different	   crosslinker	   densities	   were	   provided	   by	   EcoSynthetix	   Inc.	  (Burlington,	  ON).	  To	  avoid	  potential	  crosslinker	  toxicity,	  a	  specific	  batch	  of	  ENPs	  with	  0%	  crosslinker	  coded	  GX0	  were	  used	  in	  this	  study.	  TEMPO,	  NaBr,	  KBr,	  NaClO	  and	  ethanol	  were	  purchased	  from	  Sigma	  Aldrich	  (St.	  Louis,	  MO).	  NaOH	  was	  purchased	  from	  Mandel	  Scientific	  (Guelph,	  ON).	  All	  chemicals	  were	  used	  without	   further	  purification.	  All	  aqueous	  solutions	  were	  prepared	  using	  Milli-­‐Q	  water	  (18.2MΩ	  resistivity).	  	  	  2.3.2	  TEMPO-­‐mediated	  Oxidation	  of	  SNP	  The	  TEMPO-­‐mediated	  oxidation	  of	  ENPs	  followed	  the	  protocol	  described	  by	  Kato	  et	  al.	  2	  g	  of	  GX0	  ENPs	  were	  dispersed	  in	  50	  mL	  of	  Milli-­‐Q	  water	  at	  5%	  (w/w).	  The	  starch	  solution	  was	  kept	  at	  4	  °C	  using	  an	  ice	  bath.	  317.5	  mg	  of	  NaBr	  and	  24	  mg	  of	  TEMPO	  were	  dissolved	  individually	  with	  50	  mL	  of	  Milli-­‐Q	  water.	  Both	  NaBr	  and	  TEMPO	  solution	  was	  added	   into	  starch	  solution	  and	  the	  pH	  of	  the	  mixture	  was	  adjusted	  to	  10.75	  with	  NaOH.	  Reaction	  was	  initiated	  by	  the	  added	  aliquot	  of	  5%	  NaClO	  into	  the	  mixture.	  Aliquots	  of	  0.5M	  NaOH	  were	  constantly	   added	   to	  maintain	   reaction	   at	   pH10.75.	   After	   the	   desired	   oxidation	   level	  was	  achieved,	   excess	   ethanol	   was	   added	   into	   the	   reaction	  mixture	   to	   precipitate	   starch.	   The	  mixture	  was	  kept	  on	  ice	  to	  allow	  precipitation	  for	  30	  minutes	  before	  being	  centrifuged	  at	  7800	   rpm	   for	   20	   minutes.	   The	   supernatant	   was	   discarded	   and	   the	   pellets	   were	   re-­‐dispersed	   in	   50	   mL	   of	   Milli-­‐Q	   water.	   The	   ethanol	   precipitation	   and	   centrifugation	   was	  repeated	   again	   before	   the	   pellets	   were	   lyophilized	   overnight	   to	   obtain	   the	   powdered	  product.	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2.3.3	  Spectroscopic	  Characterization	  	  NMR	  70	  mg	   of	   oxidized	   ENPs	   were	   dispersed	   in	   700	   μL	   of	   D2O	   for	   2	   h.	   Both	   1H	   and	   13C	  spectrum	  were	  obtained	  using	  300MHz	  Bruker	  Avance	  6-­‐Channel	  NMR	  spectrometer.	  	  DLS	  and	  PALS	  Oxidized	  ENP	  samples	  were	  dispersed	  and	  diluted	  to	  1%	  (w/w)	  using	  10	  mM	  pH	  7.4	  4-­‐(2-­‐hydroxylethyl)-­‐1-­‐	  piperazineethanesulfonic	  acid	  (HEPES)	  buffer.	  Measurements	  for	  both	  particle	  size	  and	  ζ-­‐potential	  were	  done	  using	  Malvern	  Zetasizer.	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Chapter	  3.	  DNA	  Conjugation	  The	   second	   part	   of	   ENP	   modification	   is	   to	   conjugate	   aptamers	   onto	   the	   oxidized	  particles	   for	   active	   targeting.	   Oxidized	   ENPs	   from	   the	   previous	   modification	   are	   now	  capable	   of	   conjugating	   with	   amine-­‐modified	   molecules	   using	   the	   EDC/NHS	   coupling	  chemistry.	  The	  first	  objective	  is	  to	  determine	  the	  optimal	  oxidation	  level	  from	  the	  various	  samples.	  Amine-­‐modified	  dye	  molecules	  and	  control	  oligonucleotides	  were	   conjugated	   to	  evaluate	   coupling	   efficiency.	   To	   better	   visualize	   and	   quantify	   conjugation,	   conjugated	  products	  are	  subject	  to	  gel	  electrophoresis.	  And	  since	  aptamers	  are	  expensive,	  the	  last	  part	  of	   the	   process	   focuses	   on	   optimizing	   aptamer	   conjugation	   efficiency.	   Various	   reaction	  parameters	  and	  synthesis	  process	  are	  investigated	  to	  minimize	  DNA	  loss.	  	  	  
3.1	  EDC/NHS-­‐Mediated	  Aptamer	  Conjugation	  Zero-­‐length	  linkage	  refers	  to	  direct	  covalent	  bond	  linking	  an	  atom	  of	  one	  molecule	  to	  the	  other	  molecule	  without	  any	   linkers	  or	   spacers.	  The	  presence	  of	   linker	  may	  affect	   the	  affinity	   of	   targeting	   agent,	   and	   thus	   using	   zero-­‐length	   linkage	   minimizes	   potential	  complications.	   [88]	   EDC	   is	   a	   water-­‐soluble	   carbodiimide,	   widely	   used	   for	   conjugating	  biological	  substances	  containing	  amine	  and	  carboxyl	  groups.	  EDC	  can	  react	  with	  carboxyl	  to	  form	  a	  reactive	  but	  unstable	  isourea	  intermediate,	  and	  the	  intermediate	  is	  susceptible	  to	  nucleophilic	  attack	  from	  primary	  amines	  to	  form	  an	  amide	  bond.	  However,	  EDC	  is	  used	  in	  aqueous	  environment,	  and	  water	  often	  acts	  as	  a	  nucleophile	  to	  hydrolyze	  the	  intermediate.	  Therefore,	  the	  reaction	  in	  aqueous	  conditions	  often	  suffers	  from	  low	  yield.	  [89]	  To	  improve	  reaction	  yield,	   it	   is	  very	  common	  to	  add	  NHS	  during	  EDC	  coupling	  process.	  Similar	  to	  the	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EDC	  mechanism,	  the	  carboxyl	  group	  first	  forms	  the	  unstable	  intermediate	  with	  EDC.	  Then	  the	  carboxylic	  is	  transferred	  onto	  NHS	  forming	  a	  more	  stable	  ester	  bond	  (Fig.	  18).	  The	  ester	  intermediate	   is	   less	   susceptible	   to	   hydrolysis,	   but	   acts	   as	   a	   great	   leaving	   group	   in	   the	  presence	   of	   primary	   amines.	   The	   products	   of	   either	   reaction	   are	   identical,	   but	   NHS	  facilitates	  process	  produced	  significantly	  higher	  yield.	  	  	  
	  Fig.	  18	  –	  EDC/NHS	  conjugation	  mechanism.	  This	  figure	  is	  adapted	  from	  ref.	  [90].	  Copyright	  2008,	  Elsevier	  B.V.	  	  All	  the	  samples	  from	  previous	  oxidation	  steps	  were	  first	  subject	  to	  EDC/NHS	  coupling	  with	  amine-­‐modified	  dye	  molecules.	  The	  samples	  were	  also	  conjugated	  with	  amine	  and	  dye	  dual-­‐modified	   control	   DNA	   fragment	   (Cy3-­‐T15-­‐NH2).	   Denaturing	   polyacrylamide	   gel	  electrophoresis	  (PAGE)	  was	  used	  to	  evaluate	  the	  conjugation	  efficiency	  of	  each	  sample.	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  3.1.1	  Gel	  Electrophoresis	  Based	  Characterization	  Polyacrylamide	   gel	   electrophoresis	   is	   a	   technique	   widely	   used	   in	   biochemistry	   and	  molecular	   biology	   to	   separate	   biological	  macromolecules	   like	   proteins	   and	   nucleic	   acids.	  Molecules	  may	  be	  run	  in	  their	  native	  form	  to	  preserve	  their	  higher	  order	  structure	  or	  in	  a	  denatured	   form	  whose	  mobility	   is	   only	   dependent	   on	  molecule	   size	   and	  mass	   to	   charge	  ratio.	  [91]	  Since	  our	  objective	  of	  running	  gels	  is	  to	  quantify	  conjugation	  efficiency,	  there	  is	  no	  need	   to	   preserve	   DNA	   structure	   and	   therefore	   samples	   were	   denatured	   with	   urea	   and	  subject	  to	  denaturing	  PAGE.	  	  The	  first	  conjugation	  attempt	  was	  between	  oxidized	  ENPs	  and	  an	  amine-­‐modified	  dye	  molecule	   named	   HiLyte	   Fluor	   488.	   Conjugated	   samples	   were	   diluted	   appropriately	   and	  mixed	   with	   denaturant	   urea	   before	   loading	   into	   the	   gel.	   As	   shown	   in	   denaturing	   PAGE	  result,	  the	  first	  lane	  serves	  as	  the	  negative	  control	  with	  just	  the	  dye	  molecules	  and	  no	  ENPs	  (Fig.	   19).	   Although	   the	   detailed	   structure	   of	   dye	   molecules	   is	   unknown,	   seeing	   that	   the	  molecule	   migrated	   toward	   the	   cathode	   end,	   it	   is	   safe	   to	   assume	   that	   the	   molecule	   is	  negatively	  charged.	  The	  next	  two	  lanes	  are	  oxidized	  dextrin	  serving	  as	  the	  positive	  control.	  The	   most	   obvious	   contrast	   between	   the	   two	   samples	   is	   the	   difference	   in	   fluorescent	  intensity.	  The	  2%	  oxidized	  dextrin	  has	  significantly	  lower	  intensity	  than	  the	  20%	  sample.	  This	  difference	  in	  fluorescent	  intensity	  can	  also	  be	  observed	  in	  the	  oxidized	  ENP	  samples.	  The	   intensity	   seems	   to	   be	   proportional	   to	   the	   oxidation	   extent	   with	   the	   20%	   sample	  showing	  the	  highest	  intensity	  and	  non-­‐oxidized	  sample	  showing	  no	  fluorescence	  at	  all.	  This	  result	   suggests	   either	   higher	   oxidation	   levels	   are	   favourable	   for	   coupling	   process	   or	   the	  high	   fluorescence	   simply	   comes	   from	   more	   conjugation	   sites.	   Another	   interesting	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observation	   is	   the	   speed	   of	   band	   migration.	   ENPs	   are	   significantly	   larger	   than	   dye	  molecules,	   and	  are	  expected	   to	  be	   trapped	  by	   the	  gel	  without	  much	  migration.	  However,	  smeared	   bands	   suggesting	   a	   broad	   size	   distribution	   was	   observed	   with	   the	   higher	  oxidation	  samples.	  This	  result	  hints	  at	  possible	  degradation	  of	  ENPs	  during	  the	  oxidation	  process.	  	  	  
	  Fig.	  19	  –	  Denaturing	  PAGE	  results	  for	  dye	  coupled	  ENPs.	  First	  lane,	  HiLyte	  Fluor	  dye	  used	  as	  negative	  control.	  The	  next	  two	  lanes,	  2%	  and	  20%	  oxidized	  dextrin	  used	  as	  positive	  control.	  The	  remaining	  lanes	  show	  ENP	  samples	  of	  various	  oxidation	  levels.	  	  	  	   The	   coupling	   results	   between	   dye	   molecules	   and	   ENPs	   shows	   promising	   outcomes.	  Every	   oxidation	   sample	   displays	   some	   level	   of	   conjugation	   and	   the	   highest	   conjugation	  level	  is	  observed	  in	  the	  higher	  oxidation	  samples.	  The	  next	  stage	  of	  the	  coupling	  process	  is	  to	  conjugate	  control	  DNA	  onto	   the	  oxidized	  ENPs.	  Amine-­‐	  and	  Cy3-­‐modified	  control	  DNA	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Cy3-­‐T15-­‐NH2	   was	   conjugated	   with	   the	   oxidized	   samples.	   Cy3	   is	   a	   fluorescent	   dye	   with	  emission	  wavelength	  of	  570	  nm;	  its	  high	  stability	  and	  extinction	  coefficient	  is	  superior	  over	  conventional	  dyes.	  	  The	  conjugated	  products	  were	  again	  diluted	  and	  denatured	  with	  urea	  before	   loading	  into	   a	   gel.	   Despite	   the	   successful	   attempt	   for	   dye	   molecule	   coupling,	   control	   DNA	  conjugation	  was	  not	  as	  optimal.	  Conjugation	  result	  for	  control	  DNA	  was	  expected	  to	  show	  similar	   trend	   to	   dye	   coupling	   result,	   with	   the	   more	   oxidized	   samples	   display	   higher	  intensity.	   However,	   of	   all	   the	   samples	   tested,	   only	   the	   20%	   oxidized	   ENP	   sample	   shows	  minimal	  fluorescent	  intensity	  near	  the	  top	  of	  the	  well	  (Fig.	  20).	  None	  of	  the	  other	  oxidized	  samples	   show	   any	   conjugation.	   Residual	   bands	   can	   be	   seen	   migrating	   down	   the	   gel,	  indicating	   that	   majority	   of	   DNA	   was	   wasted	   and	   not	   conjugated.	   The	   low	   conjugation	  efficiency	  may	  be	  attributed	  to	  steric	  hindrance	  or	  electrostatic	  repulsion.	  The	  control	  DNA	  is	  much	  larger	  than	  the	  dye	  molecules	  used	  in	  previous	  conjugation,	  thus	  steric	  effect	  may	  have	   hindered	   the	   coupling	   process.	   Also,	   DNA	   contains	   negatively	   charged	   phosphate	  groups.	   Conjugating	  DNA	  with	   carboxyl-­‐bearing	  oxidized	  ENPs	  may	  be	  more	  difficult.	   To	  compensate	   for	   the	   low	   coupling	   efficiency,	   reaction	   parameters	   must	   be	   optimized	   to	  reduce	  DNA	  waste	  before	  conjugation	  with	  the	  aptamer.	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  Fig.	  20	  –	  Denaturing	  PAGE	  results	  for	  control	  DNA-­‐coupled	  ENPs.	  First	  lane,	  Cy3-­‐T15-­‐NH2	  used	  as	  negative	  control.	  The	  next	  two	  lanes,	  2%	  and	  20%	  oxidized	  dextrin	  used	  as	  positive	  control.	  The	  remaining	  lanes	  show	  ENP	  samples	  of	  various	  oxidation	  levels.	  	  3.1.2	  Optimization	  of	  Conjugation	  Efficiency	  To	  improve	  the	  low	  coupling	  efficiency,	  various	  reaction	  parameters	  were	  tested.	  Since	  the	  previous	  result	  shows	  minor	  coupling	  for	  only	  the	  20%	  oxidized	  ENPs,	  the	  optimization	  process	  were	  carried	  out	  using	  the	  20%	  oxidized	  ENPs	  and	  the	  control	  DNA.	  The	  first	  two	  parameters	  investigated	  were	  reaction	  time	  and	  pH.	  Original	  conjugation	  were	  done	  in	  pH	  7.6	  HEPES	  buffer	  and	  reacted	  for	  two	  hours.	  Some	  literatures	  suggest	  higher	  yield	  can	  be	  obtained	  in	  acidic	  condition	  up	  to	  pH	  4.5.	  [92],	  but	  since	  EDC	  hydrolysis	  is	  more	  potent	  at	  a	  low	  pH,	   the	   reaction	  pHs	   tested	   are	  only	   slightly	   acidic.	  As	   shown	   from	   the	  optimization	  result,	   two	  sets	  of	  reaction	  time	  and	  three	  different	  pHs	  were	  tested	  (Fig.	  21a).	   It	   is	  clear	  that	  a	  longer	  reaction	  time	  favours	  conjugation	  as	  all	  three	  samples	  that	  reacted	  overnight	  have	  stronger	  intensity	  over	  their	  counter	  parts.	  As	  for	  the	  different	  pH,	  the	  improvement	  is	  less	  significant,	  and	  the	  lower	  pH	  sample	  shows	  slightly	  better	  performance.	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  a)	   b)
	  Fig.	  21	  –	  Conjugation	  optimization	  results	  a)	  reaction	  time	  and	  pH	  b)	  temperature	  and	  DNA:ENPs	  ratio.	  A	  high	  yield	  coupling	  is	  indicated	  by	  a	  more	  intense	  band	  trapped	  in	  the	  well	  at	  the	  top	  of	  the	  gel.	  	  Following	   the	   previously	   optimized	   pH	   and	   reaction	   time,	   the	   second	   part	   of	  optimization	  focus	  on	  reaction	  temperature	  and	  reagent	  ratio.	  Conjugation	  was	  carried	  out	  at	  either	  room	  temperature,	  refrigerated	  4	  °C	  or	  slightly	  heated	  35	  °C.	  Two	  sets	  of	  DNA	  to	  ENPs	  ratios	  were	  also	  tested.	  As	  shown	  in	  Fig.	  23,	  conjugation	   in	  heated	  conditions	  show	  dramatic	  efficiency	  improvement.	  This	  might	  be	  attributed	  to	  the	  unfolding	  of	  DNA	  internal	  structure	  and	  thus	  exposing	   the	  amino	  group	   for	  conjugation.	  A	  higher	  DNA	  to	  ENP	  ratio	  also	   favours	   the	   coupling	  process.	   It	   is	  worth	  noting	   that	   the	   right	  most	   lane	  now	  shows	  stronger	  fluorescence	  from	  the	  top	  coupled	  band	  than	  the	  bottom	  residual	  DNA	  band.	  With	  this	  encouraging	  result,	  the	  conjugation	  of	  aptamer	  with	  ENPs	  was	  finally	  carried	  out	  using	  the	   optimized	   reaction	   time,	   temperature,	   pH	   and	   reagent	   ratio.	   The	   aptamer	   was	   also	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modified	   with	   fluorophore	   for	   better	   observation,	   and	   the	   coupling	   efficiency	   was	  quantified	   accordingly	   using	   the	   fluorescence	   intensity	   of	   the	   coupled	   band	   and	   the	  residual	  band.	  Aptamer-­‐coupled	  ENPs	  and	  a	  diluted	  sample	  was	  measured	  and	  the	  coupling	  efficiency	  was	  found	  to	  be	  over	  80%	  (Fig.	  22).	  	  a)	   b)
	  Fig.	  22	  –	  Aptamers	  and	  ENPs	  conjugation	  result	  a)	  denaturing	  PAGE	  results	  of	  aptamer	  coupled	  ENPs	  at	  two	  different	  concentration	  b)	  coupling	  efficiency	  quantification.	  	  
3.2	  ENPs	  Precipitation	  Throughout	   the	   EDC/NHS	   conjugation	   process,	   a	   very	   important	   technique	   was	  repeated	  multiple	  times	  to	  recover	  ENPs	  from	  the	  aqueous	  solutions.	  Ethanol	  precipitation	  is	   a	   common	   practice	   for	   precipitating	   and	   purifying	   nucleic	   acids	   and	   polysaccharides.	  
[93,94]	  Ethanol	  is	  much	  less	  polar	  than	  water;	  when	  excessive	  amount	  of	  ethanol	  are	  added	  into	   an	   aqueous	   solution,	   it	   disrupts	   the	   charge	   screening	   effect	   from	   water.	   Without	  charge	  screening,	  the	  dielectric	  groups	  on	  polysaccharides	  can	  more	  easily	  form	  ionic	  bond	  with	  ions	  in	  the	  solution	  and	  precipitate.	  During	  the	  conjugation	  process,	  ENPs	  were	  first	  
Lane	   Coupling	  Efficiency	  %	  1	   81.85%	  2	   84.64%	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reacted	  with	  EDC	  and	  NHS	  to	  activate	  the	  carboxyl	  groups.	  Activated	  ENPs	  were	  subjected	  to	  ethanol	  precipitation	  to	  remove	  the	  unreacted	  reagents	  then	  re-­‐dispersed	  back	  in	  water.	  After	   the	   conjugation	   process,	  modified	   ENPs	  were	   subject	   to	   at	   least	   two	  more	   ethanol	  precipitations	   for	   purification	   purpose.	   	   It	   is	   obvious	   that	   ethanol	   precipitation	   plays	   an	  important	   role	   in	   ENP	   modification	   scheme,	   and	   therefore	   it	   is	   vital	   to	   maximize	   ENP	  recovery	  in	  every	  precipitation.	  	  	  During	  the	  aptamer	  conjugation	  study,	  a	  few	  observations	  suggested	  the	  possibility	  of	  DNA	   affecting	   ENP	   precipitation.	   A	   simple	   experiment	   was	   carried	   out	   to	   test	   this	  hypothesis.	   Dye-­‐modified	   ENPs	  were	   synthesized	   and	   separated	   equally	   into	   three	   vials.	  For	  the	  first	  vial,	  nothing	  extra	  was	  added	  into	  the	  sample.	  For	  the	  second	  and	  the	  third	  vial,	  equal	  amounts	  of	  DNA	  were	  added.	  DNA	  for	  vial	   two	  was	  not	  modified,	  whereas	  DNA	  for	  vial	   three	   has	   fluorescent	   labels.	   All	   three	   samples	  were	   subject	   to	   ethanol	   precipitation	  three	   times	   before	   the	   precipitates	   were	   re-­‐dispersed	   in	   water	   and	   observed	   with	  denaturing	  PAGE	  (Fig.	  23).	  Sample	  one	  precipitated	  without	  DNA	  displayed	  strikingly	  low	  recovery	  compared	  to	  sample	  two	  and	  three.	  Sample	  three	  also	  shows	  that	  DNA	  facilitates	  ENP	  precipitation,	  and	  DNA	  is	  not	  associated	  with	  ENPs.	  The	  free	  DNA	  can	  be	  clearly	  seen	  at	  the	  bottom	  of	  the	  gel	  as	  a	  red	  band	  since	  it	  is	  labeled	  with	  a	  different	  fluorophore.	  The	  interaction	  between	  DN	  and	  oxidized	  ENP	  is	  possibly	  through	  ionic	  interaction	  in	  ethanol	  mediated	  by	  salt.	  Once	  dispersed	  in	  water,	  they	  can	  be	  easily	  separated.	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  Fig.	  23	  –	  ENPs	  precipitation	  test	  1)	  5%	  (w/w)	  dye-­‐modified	  ENPs	  precipitated	  using	  ethanol.	  2)	  5%	  (w/w)	  dye-­‐modified	  ENPs	  +	  non-­‐labeled	  DNA	  precipitated	  with	  ethanol.	  3)	  5%	  (w/w)	  dye-­‐modified	  ENPs	  +	  fluorophore-­‐labeled	  DNA	  precipitated	  with	  ethanol.	  	  	  With	   this	   result,	   further	   testing	  was	   done	   to	   quantify	   the	   recovery	   efficiency	   and	   to	  explore	  better	  precipitation	  methods.	  Dye-­‐modified	  ENPs	  were	  used	  again	  with	  different	  solvents	   and	   additives	   for	   precipitation.	   Precipitates	  were	  measured	  with	   a	   fluorometer	  and	   calibrated	  with	   an	   external	   standard	   to	   calculate	   the	   recovery	   efficiency.	   The	   result	  suggests	   that	   pure	   ethanol	   precipitation	   has	   a	   low	   recovery	   of	   less	   than	   40%,	   and	   even	  lower	   with	   methanol	   (Fig.	   24).	   However,	   precipitation	   with	   isopropanol	   significantly	  improved	   the	   efficiency	   up	   to	   90%.	   Samples	   with	   additives	   were	   also	   precipitated	   with	  ethanol.	  As	  expected,	  the	  addition	  of	  DNA	  greatly	  improved	  ethanol	  recovery.	  However,	  the	  addition	  of	  PEG	  and	  salt	  shows	  much	  less	  improvement.	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  Fig.	  24	  –	  ENPs	  precipitation	  recovery	  assay.	  5%	  (w/w)	  dye-­‐modified	  ENPs	  precipitated	  with	  different	  solvents.	  Dye-­‐modified	  ENPs	  mixed	  with	  different	  additive,	  then	  precipitated	  with	  ethanol.	  	  	  With	   the	   highest	   recovery	   rate,	   isopropanol	   temporarily	   replaced	   ethanol	   for	  precipitation	  and	  its	  precipitation	  capability	  consistently	  out-­‐performed	  the	  other	  method.	  However,	  it	  was	  later	  discovered	  that	  isopropanol	  precipitation	  has	  a	  detrimental	  effect	  on	  the	   subsequent	   internalization	   study.	   Therefore,	   the	   final	   precipitation	   protocol	   was	  adjusted	  back	  to	  ethanol	  precipitation	  with	  the	  addition	  of	  salt.	  Although	  not	  as	  potent	  as	  isopropanol,	  the	  addition	  of	  salt	  can	  greatly	  improve	  ethanol’s	  recovery	  (Fig.	  25).	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  Fig.	  25	  –	  5%	  (w/w)	  dye-­‐modified	  ENP	  precipitated	  with	  1)	  100%	  isopropanol,	  2)	  100%	  ethanol,	  3)	  100%	  ethanol	  +	  10	  μL	  of	  50	  mM	  MgCl2	  salt.	  	  	  
3.3	  Materials	  and	  Methods	  3.3.1	  Materials	  Isopropanol,	   ethanol,	   EDC,	   and	   NHS	   were	   purchased	   from	   Sigma-­‐Aldrich	   (St.	   Louis,	  MO).	   HEPES	   and	   MES	   buffer	   were	   purchased	   from	   Amresco	   (Solon,	   OH).	   PEG	   8K	   was	  purchased	   from	  Alfa	  Aesar	  (Ward	  Hill,	  MA).	  Control	  DNA	  was	  purchased	   from	  Integrated	  DNA	   technologies	   (Coralville,	   IA).	   Aptamer	   AS1411	   was	   purchased	   from	   Eurofins	  (Huntsville,	   AL).	   Amine	   modified	   dye	   molecule	   HiLyte	   Fluor	   488	   was	   purchased	   from	  AnaSpec	   (Fremont,	   CA).	   All	   chemicals	   were	   used	   without	   any	   further	   purification.	   All	  aqueous	  solutions	  were	  prepared	  using	  Milli-­‐Q	  water	  (18.2	  MΩ	  resistivity).	  	  3.3.2	  EDC/NHS	  Aptamer	  Conjugation	  The	   following	   protocol	   describes	   the	   optimized	   reaction	   condition	   for	   the	   EDC/NHS	  conjugation.	  The	  oxidized	  ENPs	  were	  dispersed	  in	  Milli-­‐Q	  water	  at	  5%	  (w/w).	  40	  μL	  of	  ENP	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solution,	  40	  μL	  of	  0.5	  M	  pH	  6.0	  MES	  buffer,	  40	  μL	  of	  0.5	  M	  EDC	  and	  40	  μL	  of	  0.025	  M	  NHS	  were	   mixed	   consecutively.	   The	   reaction	   vial	   was	   placed	   on	   a	   block	   heater	   overnight	   at	  35	  °C.	  10	  μL	  of	  10	  mM	  MgCl2	  was	  added	  into	  the	  reaction	  mixture	  before	  precipitation	  with	  1	  mL	  of	  ethanol.	  The	  precipitate	  was	  cooled	  in	  the	  fridge	  for	  15	  minutes	  and	  centrifuged	  at	  15000	  rpm	  for	  5	  minutes	   to	  recover	  activated	  ENPs.	  ENPs	  were	  re-­‐dispersed	   in	  40	  μL	  of	  Milli-­‐Q	  water	   and	   the	   aptamer/dye	   solution	  was	   added.	   The	   reaction	  was,	   again,	   left	   on	  block	  heater	  for	  12	  hours	  then	  precipitated	  with	  ethanol	  and	  salt	  for	  two	  more	  times	  before	  re-­‐dispersed	  in	  40	  μL	  of	  Milli-­‐Q.	  	  	  3.3.3	  Gel	  Electrophoresis	  	  To	   prepare	   for	   the	   poly-­‐acrylamide	   gel,	   22	  mL	   of	   10%	   polyacrylamide	   solution	  was	  mixed	   with	   50	   μL	   of	   10%	   ammonium	   persulfate	   (APS),	   and	   20	   μL	   of	  tetramethylethylenediamine	   (TEMED).	   	  The	  mixture	  was	   loaded	   into	  a	  prepared	  molding	  cassette	  and	  set	  for	  40	  minutes.	  Sample	  wells	  were	  washed	  three	  times	  with	  buffer.	  Testing	  samples	  were	  mixed	  with	   equal	   amounts	   of	   8	  M	   urea	   before	   loading	   into	   sample	  wells.	  Denaturing	  PAGE	  was	  ran	  at	  500	  V,	  250	  mA	  and	  30	  W	  for	  40	  minutes.	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Chapter	  4.	  Cellular	  Uptake	  of	  ENPs	  The	   last	   chapter	   of	   this	   thesis	   is	   to	   test	   our	   vehicle’s	   capability	   in	   terms	   of	   selective	  cellular	   internalization.	  The	  ENPs	  have	  been	  modified	  with	  aptamers	   for	  active	   targeting.	  Therefore,	   the	   first	   task	   is	   to	   investigate	   whether	   or	   not	   cancer	   cells	   can	   selectively	  internalize	  the	  aptamer-­‐modified	  vehicle.	  To	  visualize	  internalization,	  the	  ENPs	  are	  either	  directly	   modified	   with	   dye	   molecules	   or	   the	   attached	   aptamers	   have	   fluorescent	   labels.	  Internalization	   studies	   were	   observed	   and	   imaged	   using	   fluorescence	   microscopy.	   The	  internalization	  results	  are	  compared	  against	  liposome-­‐based	  vehicles.	  	  
4.1	  Cellular	  Internalization	  The	   aptamer	   used	   for	   the	   previous	   conjugation	   is	   AS1411.	   AS1411	   is	   a	   26-­‐base	  guanine-­‐rich	   DNA	   aptamer	   with	   the	   sequence	   5’-­‐GGTGGTGGTGGTTGTGGTGGTGGTGG.	  Among	   all	   the	   therapeutic	   aptamers,	   AS1411	   is	   one	   of	   the	   most	   advanced	   aptamer	   for	  cancer	  treatment.	  [95]	  In-­‐vivo	  studies	  for	  AS1411’s	  antitumor	  activity	  suggest	  delayed	  tumor	  growth	  for	  renal	  cancer,	  lung	  cancer,	  and	  breast	  cancer	  xenograft.	  Phase	  I	  clinical	  trials	  also	  show	  promising	  result	  of	  stabilizing	  cancer	  growth.	  [96]	  	  Aside	   from	   the	   growth	   inhibition	   capability,	   AS1411	   also	   shows	   strong	   affinity	   to	  specific	  cancer	  cells	  [97]	  like	  the	  MCF-­‐7	  breast	  cancer,	  MV4-­‐11	  Leukemia,	  and	  HeLa	  cervical	  cancer	   cells.	   Research	   has	   attributed	   this	   phenomenon	   to	   AS1411’s	   affinity	   toward	   the	  nucleolin	  protein	  on	   the	  plasma	  membrane.	  AS1411	  oligonucleotides	  usually	  dimerize	   to	  form	   a	   higher	   structure	   consisting	   of	   eight	   G-­‐quartets.	   The	   G-­‐quartets’	   structure	   greatly	  improves	  the	  aptamers’	  stability	  and	  is	  essential	  for	  AS1411’s	  affinity	  towards	  nucleolin.	  [98]	  Nucleolin	   is	   generally	   a	   nucleolar	   protein	   but	   can	   sometimes	   be	   found	   on	   the	   cell	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membrane	  surface.	  The	  membrane	  nucleolin	  has	  relatively	  low	  expression	  on	  normal	  cells	  but	   is	   overexpressed	   on	   many	   different	   types	   of	   cancer	   cells.	   The	   membrane	   nucleolin	  works	   in	   conjunction	   with	   actin	   filaments	   and	   acts	   as	   a	   shuttling	   protein	   between	   the	  cytoplasm	   and	   the	   nucleus.	   [99]	   The	   detailed	  mechanism	   of	   action	   for	   AS1411	   is	   still	   not	  clear,	   but	   studies	   have	   shown	   that	   once	   AS1411	   binds	   with	   a	   membrane	   nucleolin,	   it	  triggers	   internalization.	   The	   aptamer	   and	   nucleolin	   complex	   further	   interact	   with	   other	  cofactors	  and	  eventually	  inhibits	  DNA	  replication	  (Fig.	  26).	  
	  Fig.	  26	  –	  Proposed	  AS1411	  mechanism	  of	  action.	  AS1411	  oligonucleotides	  dimerize	  to	  form	  eight	  G-­‐quartets	  and	  interact	  with	  membrane	  nucleolin	  to	  trigger	  internalization.	  This	  figure	  is	  adapted	  from	  ref.	  [98].	  Copyright	  2006,	  American	  Association	  for	  Cancer	  Research.	  	  
4.2	  Microscopic	  Imaging	  	  4.2.1	  Epifluorescence	  Microscopy	  The	  internalization	  results	  were	  first	  observed	  using	  epifluorescence	  microscopy.	  For	  sample	  preparation,	  aptamer-­‐	  and	  control	  DNA-­‐modified	  ENP	  samples	  were	  incubated	  with	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HeLa	  cells	   in	  96-­‐well	  plate.	  50	  nm	  fluorescein	   isothiocyanate	  (FITC)-­‐labeled	  silicon	  beads	  were	  also	  incubated	  with	  HeLa	  cells	  and	  used	  as	  positive	  control.	  For	  better	  visualization,	  cell	  nuclei	  were	  stained	  with	  the	  Hoechst	  33258	  dye.	  The	  illustrations	  on	  the	  left	  represent	  the	   samples	   incubated	   with	   cells.	   The	   dashed	   circle	   represents	   an	   ENP,	   the	   filled	   circle	  represents	  a	  silicon	  bead,	  the	  folded	  line	  represents	  the	  aptamer	  AS1411,	  the	  unfolded	  line	  represents	  control	  DNA	  and	  star	  represents	  fluorophore	  (Fig.	  27).	  The	  blue	  channel	  shows	  the	  stained	  cell	  nuclei,	  the	  green	  channel	  shows	  the	  signal	  from	  ENPs	  or	  silicon	  beads	  and	  the	  merged	  channel	  displays	  a	  stacking	  image	  of	  all	  three	  channels	  to	  show	  localization.	  A	  number	  of	  problems	  were	  discovered	  from	  this	  initial	  result.	  Firstly,	  the	  cell	  nuclei	  show	  no	  obvious	   signal	   even	   under	   strong	   exposure.	   Secondly,	   ENP	   samples	   display	   no	  internalization.	   The	   signal	   observed	   from	   the	   positive	   control	   is	   much	   stronger	   but	  contains	   a	   lot	   of	   background	   fluorescence	   in	   areas	   where	   cells	   are	   not	   present.	   These	  defects	  are	  possibly	  caused	  by	  live	  observation	  as	  live	  cells	  have	  lower	  staining	  efficiency.	  Therefore,	   to	   better	   evaluate	   modified	   ENPs’	   internalization,	   a	   different	   staining	   and	  imaging	  technique	  is	  required.	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  Fig.	  27	  –	  Epifluorescence	  microscopy	  images	  of	  cellular	  internalization	  assay.	  From	  top	  to	  bottom,	  aptamer-­‐modified	  ENPs,	  random	  DNA-­‐modified	  ENPs	  as	  negative	  control,	  and	  dye-­‐modified	  50	  nm	  silicon	  beads	  as	  positive	  control.	  	  4.2.2	  Confocal	  Laser	  Scanning	  Microscopy	  Confocal	   microscopy	   is	   an	   advanced	   technique	   of	   fluorescence	   microscopy	   with	   a	  significant	  improvement	  on	  optical	  resolution	  and	  contrast.	  This	  improvement	  comes	  from	  the	  addition	  of	  optical	  pinholes	  at	  both	  the	  light	  source	  and	  the	  detector	  to	  eliminate	  out	  of	  focus	   light.	   The	   cellular	   samples	   subject	   to	   confocal	   microscopy	   were	   also	   fixed	   with	  paraformaldehyde	   and	   stained	   with	   4’,6-­‐diamidino-­‐2-­‐phenylindole	   (DAPI).	   The	   same	  samples	   from	   previous	   epifluorescence	   microscopy	   attempts	   were	   incubated	   with	   HeLa	  cells	  on	  circular	  coverslips	  in	  a	  24-­‐well	  plate.	  Compared	  with	  the	  previous	  result,	  confocal	  images	   have	  much	   higher	   resolution	   and	   stronger	   contrast	   (Fig.	   28).	   Cell	   nuclei	   are	   also	  clearly	  visible	  with	  DAPI	  stain.	  It	  is	  important	  to	  note	  that	  the	  images	  were	  acquired	  under	  different	   imaging	  parameters	  to	  showcase	  the	  contrast	  between	  confocal	  microscopy	  and	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epifluorescence	  microscopy.	  No	  quantitative	   comparison	   can	  be	  made	  between	   the	   three	  tested	  samples.	  
	  Fig.	  28	  –	  Confocal	  microscopy	  images	  of	  cellular	  internalization	  assay.	  From	  top	  to	  bottom,	  aptamer-­‐modified	  ENPs,	  random	  DNA-­‐modified	  ENPs	  as	  negative	  control,	  and	  dye-­‐modified	  50	  nm	  silicon	  beads	  as	  positive	  control.	  Blue	  channel	  shows	  stained	  nuclei,	  green	  channel	  shows	  fluorescent	  from	  aptamers,	  ENPs	  or	  silicon	  beads.	  	  
4.3	  Vehicle	  Internalization	  Assay	  	  With	   the	   proper	   imaging	   technique	   to	   visualize	   cellular	   internalization,	   different	  samples	  of	  modified	  ENPs	  were	  synthesized	  to	  evaluate	  the	  vehicle’s	  capability.	  	  	  4.3.1	  Aptamer	  Density	  The	  first	   internalization	  study	  is	  to	  investigate	  the	  effect	  of	  aptamer	  density	  on	  ENPs.	  Three	  samples	  of	  modified	  ENPs	  were	  prepared,	  one	  with	  no	  aptamers	  but	  dye	  molecules	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and	   the	   two	  other	   samples	  have	  different	  ENP:aptamer	  molar	   ratio	  at	  1:1	  and	  1:0.2.	  The	  ENP:DNA	   ratios	   were	   calculated	   based	   on	   the	   assumption	   of	   ENP	   molar	   weight	   of	   106	  Dalton.	   All	   the	   imaging	   parameters	   were	   kept	   consistent	   for	   unbiased	   comparison.	   As	  shown	   in	   confocal	   images,	   both	   samples	   of	   aptamer-­‐modified	   ENPs	   display	   clear	  internalization.	   Interestingly,	   dye-­‐modified	   ENPs	   also	   show	   strong	   internalization	  comparable	   to	   the	   high	   aptamer	   ratio	   sample.	   It	   needs	   to	   be	   pointed	   out	   here	   that	   the	  fluorophore	   label	   is	   starch	   for	   this	   sample,	  while	   the	   two	   DNA	   containing	   samples	   have	  their	   label	   on	  DNA.	  Therefore,	   the	   fluorescence	   intensity	   of	   these	   samples	   is	   not	  directly	  comparable.	  This	  result	  suggests	  ENPs	  can	  be	  internalized	  by	  HeLa	  cells	  without	  the	  help	  of	  aptamers.	  As	  for	  aptamer	  modification,	  the	  effect	  of	  aptamer	  density	  is	  not	  conclusive.	  	  	  
	  Fig.	  29	  –	  Internalization	  assay,	  aptamer	  density	  study.	  From	  top	  to	  bottom,	  dye-­‐modified	  ENPs,	  high	  aptamer-­‐ratio	  aptamer-­‐modified	  ENPs,	  low	  aptamer-­‐ratio	  aptamer-­‐modified	  ENPs.	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4.3.2	  Dual-­‐Labeled	  Vehicle	  Assay	  To	   further	   validate	   ENPs’	   internalization	   and	   aptamers’	   density	   effect,	   dual-­‐labeled	  modified	  ENPs	  were	  prepared.	  ENPs	  were	  first	  conjugated	  with	  Cy5	  labeled	  AS1411	  then	  with	   HiLyte	   Fluor	   488	   dye.	   The	   dual-­‐labeled	   ENPs	   can	   be	   observed	   under	   a	   different	  wavelength	  to	  probe	  co-­‐localization.	  HeLa	  cells’	  actin	  filaments	  were	  also	  stained	  to	  better	  visualize	   ENPs’	   intracellular	   location.	   The	   green	   channel	   shows	   ENPs’	   location,	   the	   red	  channel	   shows	   aptamer	   fluorescence	   and	   the	   yellow	   channel	   shows	   the	   approximate	  location	   of	   the	   cell	  membrane.	   As	   shown	   in	   the	   confocal	   images,	   the	   dual-­‐labeled	   ENPs’	  internalization	   result	   is	   in	   good	   agreement	  with	   the	   previous	   attempt.	   The	   dye	  modified	  ENP	  sample	  displays	  clear	  internalization	  (Fig.	  30).	  Both	  of	  the	  aptamer-­‐modified	  samples	  were	  internalized.	  Most	  of	  the	  signals	  observed	  in	  red	  channel	  are	  co-­‐localized	  with	  ENPs’	  fluorescence.	   This	   overlap	   further	   confirms	   that	   the	   signal	   observed	   is	   from	   aptamer-­‐modified	  ENPs	  and	  not	  from	  non-­‐specific	  fluorescence.	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  Fig.	  30	  –	  Internalization	  assay,	  duo	  labeled	  ENPs.	  From	  top	  to	  bottom,	  the	  negative	  control	  contained	  no	  samples,	  dye-­‐modified	  ENPs,	  low	  aptamer-­‐ratio	  aptamer-­‐modified	  ENPs,	  high	  aptamer-­‐ratio	  aptamer-­‐modified	  ENPs.	  	  	  	  
4.4	  Vehicle	  Selectivity	  Assay	  	  The	  second	  part	  of	  the	  modified	  ENPs’	  evaluation	  investigates	  the	  vehicle’s	  specificity.	  As	  mentioned	   previously,	   one	   of	   the	  major	   problems	   for	   chemotherapy	   is	   unintentional	  cytotoxicity.	   It	   is	   highly	   desirable	   for	   a	   drug	   delivery	   vehicle	   with	   the	   capability	   to	  distinguish	  its	  target.	  AS1411’s	  affinity	  toward	  nucleolin	  facilitates	  ENP	  targeting	  and	  HeLa	  cell	   internalization.	  Theoretically,	  conjugating	  another	  aptamer	  with	  a	  different	  molecular	  target	   would	   significantly	   reduce	   the	   vehicle’s	   selective	   internalization.	   Sgc8	   is	   a	   DNA	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aptamer	   selected	   using	   cell-­‐SELEX	   with	   strong	   affinity	   towards	   acute	   lymphoblastic	  leukemia.	  [100]	  Studies	  have	  shown	  sgc8’s	  molecular	  target	  is	  also	  a	  membrane	  protein	  but	  instead	  of	  nucleolin,	  sgc8	  binds	  to	  tyrosine	  kinase.	  [101]	  Four	  samples	  of	  aptamer-­‐modified	  ENPs	   were	   made	   to	   test	   vehicle’s	   selectivity.	   Two	   samples	   with	   AS1411	   at	   different	  ENP:DNA	   ratio	   and	   the	   other	   two	   with	   sgc8.	   AS1411-­‐conjugated	   samples	   behaved	   as	  expected,	   internalization	   was	   observed	   and	   aptamer	   fluorescence	   co-­‐localized	   with	   the	  ENP	   signal	   (Fig.	   31).	   On	   the	   contrary,	   sgc8-­‐modified	   samples	   showed	   no	   obvious	  internalization.	  The	   aptamer	   signal	   shows	  no	   response	   and	   the	   slight	   green	   fluorescence	  might	  be	  caused	  by	  the	  non-­‐conjugated	  ENPs.	  This	  result	  demonstrated	  the	  highly	  selective	  nature	  of	  aptamer	  conjugated	  ENPs.	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  Fig.	  31	  –	  Vehicle	  selectivity	  assay.	  The	  first	  two	  samples	  are	  AS1411-­‐modified	  ENPs	  (HeLa	  targeting)	  at	  two	  different	  aptamers:ENPs	  ratios.	  The	  bottom	  two	  samples	  are	  sgc8-­‐modified	  ENPs	  (non-­‐HeLa	  targeting)	  at	  the	  same	  two	  ratios.	  	  	  
4.5	  Internalization	  Efficacy	  Comparison	  –	  Liposome	  The	   previous	   assays	   reveal	   the	  modified	   ENPs’	   capability	   in	   terms	   of	   internalization	  and	   selectivity.	   For	   the	   purpose	   of	   comprehensive	   study,	   modified	   ENPs	   are	   subject	   to	  benchmarking	  against	  the	  market	  standard	  liposome.	  The	  liposomes	  tested	  composed	  of	  94%	  1,2-­‐Dioleoyl-­‐sn-­‐glycero-­‐3-­‐phosphocholine	   (DOPC),	   5%	   MPB-­‐PE	   and	   1%	   Rhodamine-­‐
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labeled	  DOPC.	  Liposomes	  were	  extruded	  through	  100	  nm	  membrane,	  which	  yielded	  mean	  size	  of	  around	  114	  nm.	  The	  addition	  of	  MPB-­‐PE	  provides	  conjugation	  site	  for	  thiolated	  DNA.	  	  Rhodamine-­‐labeled	   liposomes	   were	   conjugated	   with	   thiol-­‐modified	   AS1411	   before	  being	   subjected	   to	   the	   internalization	   test.	   As	   shown	   in	   the	   test	   result,	   both	   aptamer-­‐modified	  ENPs	  and	   liposome	  show	  significant	  cellular	  uptake.	  Nonetheless,	  uptake	  extent	  in	   the	   liposome	  sample	   is	  much	  higher	   than	   the	  ENP	  sample.	  Another	   important	  detail	   is	  that	  the	  ENP	  sample	  concentration	  is	  orders	  of	  magnitude	  higher	  than	  the	  liposome	  sample.	  The	   difference	   in	   concentration	   further	   amplifies	   the	   contrast	   in	   internalization	   efficacy.	  The	  non-­‐modified	  liposome	  shows	  no	  internalization.	  	  It	   is	   interesting	   that	   the	   initial	   result	   suggests	   similar	   uptake	  behaviour	   for	   both	   the	  modified,	   and	   non-­‐modified	   liposome	   (Fig.	   32).	   Cellular	   internalization	   of	   non-­‐modified	  liposome	   is	   caused	  by	   the	  binding	  of	   serum	  protein	   to	   the	  non-­‐conjugated	  MPB-­‐PE	  sites.	  Thiol	   group	   of	   cysteine	   residues	   on	   serum	   protein	   can	   forms	   covalent	   bond	   with	   the	  maleimide	   group	   on	   MPB-­‐PE.	   The	   protein-­‐coated	   liposome	   is	   favourable	   for	   cellular	  internalization.	   Capping	   the	   conjugation	   site	   with	   mercaptoethanol	   compensated	   this	  artefact.	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  Fig.	  32	  –	  Internalization	  comparison,	  aptamer	  modified	  ENPs,	  aptamer	  modified	  liposomes	  and	  dye-­‐labeled	  liposomes.	  	  	  
4.6	  Materials	  and	  Methods	  4.6.1	  Materials	  Fluoromount,	   BSA	   and	   Triton	   X-­‐100	   were	   purchased	   from	   Sigma	   Aldrich	   (St.	   Louis,	  MO).	  Mercaptoethanol	  was	  purchased	  from	  Alfa	  Aesar	  (Ward	  Hill,	  MA).	  Paraformaldehyde	  and	  Alexa	  Fluor	  448	  Phalloidin	  dye	  were	  purchased	  from	  Fisher	  Scientific	  (Waltham,	  MA).	  Dulbecco’s	   Modified	   Eagle	   Medium	   (DMEM)	   and	   Dulbecco’s	   Phosphate	   Buffered	   Saline	  (DPBS)	  were	  purchased	  from	  Lonza	  (Allendale,	  NJ).	  DOPC,	  Rhodamine	   labeled	  DOPC,	  and	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MPB-­‐PE	  were	  purchased	   from	  Avanti	   (Alabaster,	  AL).	  Dithiothreitol	  was	  purchased	   from	  Amresco	   (Solon,	   OH).	   Cy5	   labeled	   AS1411	   and	   thiolated	   AS1411	   were	   purchased	   from	  Eurofin	  (Huntsville,	  AL).	  Sep	  Pak	  column	  was	  purchased	  from	  Waters	  (Mississauga,	  ON).	  All	  chemicals	  were	  used	  without	  any	  further	  purification.	  All	  aqueous	  solutions	  were	  prepared	  using	  Milli-­‐Q	  water	   (18.2	  MΩ	   resistivity).	   HeLa	   cell	   line	   (CCL-­‐TM)	  was	   obtained	   from	   the	  American	  Type	  Culture	  Collection	  (ATCC	  Manassas,	  Virginia)	  through	  the	  help	  of	  Dr.	  Shirley	  Tang	  (Waterloo,	  ON).	  	  	  4.6.2	  Cell	  Culture	  HeLa	  cells	  were	  cultured	  with	  DMEM/F12	  medium	  containing	  10%	  (v/v)	  fetal	  bovine	  serum,	   10%	   (v/v)	   of	   100	  U/mL	  penicillin-­‐streptomycin	   and	   incubated	   in	   humidified	   5%	  CO2	   incubator	   at	   37	   °C.	   Cells	   were	   seeded	   onto	   14	   mm	   coverslips	   in	   a	   24-­‐well	   plate	   at	  density	  of	  20,000	  cells	  per	  well.	  500	  μL	  of	  culture	  medium	  were	  added	   into	   the	  well	  and	  incubated	   overnight	   before	   adding	   10	   μL	   of	   samples.	   Cellular	   samples	   were	   incubated	  overnight	  before	  fixing	  and	  staining.	  	  4.6.3	  Confocal	  Laser	  Scanning	  Microscopy	  The	   following	  protocol	  describes	  the	  sample	  preparation	  and	  staining	  procedures	   for	  confocal	   laser	   scanning	   microscopy.	   Sample-­‐containing	   medium	   were	   removed	   and	   the	  coverslips	   were	   washed	   twice	   with	   500	   μL	   of	   DPBS.	   Cells	   were	   fixed	   200	   μL	   of	   4%	  paraformaldehyde	  for	  10	  minutes	  at	  room	  temperature.	  Cells	  were	  washed	  twice	  with	  500	  μL	  DPBS	  after	   fixing.	  200	  μL	  of	  0.1%	  Triton	  X-­‐100	  was	  added	   to	  cells	   for	  3	   to	  5	  minutes,	  then	  washed	   two	  more	   times	  with	  500	  μL	  DPBS.	  Fixed	  cells	  were	   incubated	  with	  200	  μL	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DPBS	  containing	  1%	  BSA	  for	  20	  minutes	  to	  prevent	  non-­‐specific	  staining.	  Cells	  were	  again	  washed	   twice	   with	   DPBS	   then	   stained	   with	   Alexa	   Fluor	   448	   Phalloidin	   dye	   at	   1	   unit	  concentration	   per	   sample	   for	   20	   minutes	   at	   room	   temperature.	   Samples	   were	   washed	  twice	  again	  with	  DPBS	  before	  the	  final	  staining	  with	  200	  μL	  of	  2%	  DAPI	  for	  5	  minutes.	  The	  final	   samples	  were	  washed	   and	   submerged	   in	   DPBS.	   30	   μL	   for	   Fluoromount	  was	   added	  onto	  cleaned	  microscope	  slide,	  and	  the	  sample	  coverslip	  was	  placed	  cell	  side	  down	  onto	  the	  Fluoromount	  droplet.	  Slides	  were	  left	  to	  dry	  overnight	  before	  ready	  to	  be	  observed	  under	  the	  microscope.	  Samples	  were	  observed	  and	  imaged	  using	  a	  Zeiss	  LSM	  510	  Meta	  Confocal	  Microscope.	  	  	  4.6.4	  Liposome	  Preparation	  Thiol-­‐modified	   AS1411	   was	   activated	   with	   dithiothreitol	   for	   one	   hour	   at	   room	  temperature.	  The	  activated	  DNA	  was	  passed	  through	  a	  Sep	  Pak	  column	  to	  de-­‐salt	  and	  was	  quantified	   using	   a	   NanoDrop	   UV-­‐Vis	   Spectrophotometer.	   Prepared	   114	   nm	   DOPC	  liposomes	  containing	  5%	  MPB-­‐PE	  and	  1%	  Rhodamine-­‐labeled	  DOPC	  were	  diluted	  to	  10nM	  using	  HEPES.	  1	  μL	  of	  activated	  AS1411	  were	  conjugated	  with	  50	  μL	  of	  10	  nM	  liposomes	  in	  100	  μL	  of	  10	  mM	  pH	  7.4	  HEPES	  overnight.	  The	  DNA-­‐modified	  liposomes	  were	  precipitated	  using	   centrifugation	   (130000	   rpm)	   at	   4	   °C,	   the	   supernatant	   was	   removed	   and	   the	  precipitates	  were	  re-­‐dispersed	  in	  10	  mM	  HEPES.	  	  	   	  
	  	   58	  
Chapter	  5.	  Conclusion	  and	  Recommendations	  
5.1	  Conclusion	  This	   thesis	  began	  with	  an	  examination	  of	  global	  cancer	  pandemic	  and	  cancer	  history.	  The	   examination	   is	   followed	   by	   a	   comprehensive	   review	   of	   the	   three	   major	   cancer	  treatments,	   surgical	   operation,	   radiation	   therapy	   and	   chemotherapy.	   Chemotherapeutics	  were	   reviewed	   in	   detail	   and	   one	   of	   the	   solutions	   for	   its	   non-­‐specific	   cytotoxicity	   is	   to	  incorporate	   drugs	   within	   targeted	   delivery	   vehicles.	   Targeted	   drug	   delivery	   was	   then	  investigated	   in	   detail	   in	   terms	   of	   targeting	   methods,	   vehicle	   compositions,	   and	  biocompatibility.	  Seeing	  that	  biodegradable	  nanoparticles	  have	  attracted	  much	  attention	  in	  the	   field	  of	  drug	  delivery,	   the	   focus	   then	  shifted	  onto	  polysaccharides-­‐based	  systems	  and	  more	   specifically	   starch	   nanoparticles.	   After	   an	   in-­‐depth	   review	   of	   starch’s	   fundamental	  characteristics	   and	   its	   applications,	   we	   recognized	   that	   a	   commercially	   available	   starch	  nanoparticle	   named	  EcoSphereTM	   serves	   as	   an	   excellent	   platform	   for	   anticancer-­‐targeted	  drug	   delivery.	   Two	   major	   modifications	   were	   proposed	   to	   improve	   ENPs’	   targeting	  capability,	   namely	   oxidation	   and	   aptamer	   conjugation.	   The	   final	   study	   focused	   on	  evaluating	  the	  modified	  vehicle’s	  capabilities	  such	  as	  cellular	  internalization	  and	  selectivity.	  	  The	   first	  modification	  equipped	  ENPs	  with	   conjugation	   sites	   for	   subsequent	   aptamer	  coupling.	   Specifically,	   C6	   hydroxyls	   on	   glucose	   units	   were	   partially	   oxidized	   to	   carboxyl	  groups	  using	  TEMPO	  catalyst.	  1%,	  2%,	  5%,	  10%,	  and	  20%	  partially	  oxidized	  ENP	  samples	  were	   prepared.	   Spectroscopic	   measurements	   were	   used	   to	   confirm	   oxidation	   and	  characterize	  oxidized	  ENPs’	  properties.	  1H	  NMR	  confirmed	  oxidation	  with	  9.1ppm	  aldehyde	  shift	   showing	   signal	   strength	   proportional	   to	   oxidation	   level.	   13C	   NMR	   displayed	   two	  carbonyl	   shifts	   representing	   the	   two	   oxidized	   product,	   aldehyde	   and	   carboxyl.	   All	   of	   the	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oxidized	   samples	   subject	   to	  FTIR	   showed	  significant	   carbonyl	  peak	  at	   around	  1600	  cm-­‐1.	  DLS	   size	   measurements	   suggested	   possible	   ENP	   aggregation	   for	   the	   higher	   oxidized	  samples.	   And	   finally,	   ζ-­‐potential	   measurements	   showed	   decreasing	   trend	   along	   with	  increasing	  carboxyl	  groups	  for	  the	  oxidized	  samples.	  	  The	  second	  modification	  utilized	  ENP’s	  newly	  introduced	  carboxyl	  groups	  for	  aptamers	  conjugation.	   Zero-­‐length	   linkage	   between	   ENP	   carboxyl	   and	   amine-­‐modified	   aptamers	  were	   accomplished	   through	   EDC/NHS	   conjugation.	   Every	   sample	   from	   the	   previous	  modification	  was	   first	   conjugated	  with	  dye	  molecules	  and	  control	  DNA	   to	   investigate	   the	  optimal	   oxidation	   level	   for	   conjugation.	   Conjugated	   products	   were	   analyzed	   using	  denaturing	   PAGE	   and	   the	   initial	   result	   only	   showed	   successful	   coupling	   with	   the	   dye	  molecules.	   Minor	   DNA	   conjugation	   was	   observed	   for	   only	   the	   20%	   oxidized	   ENPs.	   To	  improve	   DNA	   conjugation	   efficiency,	   reaction	   parameters	   were	   optimized	   for	   time,	  temperature,	   pH	   and	   reagent	   ratios.	   Using	   the	   optimized	   reaction	   conditions,	   aptamers	  were	  coupled	  with	  20%	  oxidized	  ENPs	  and	  the	  coupling	  efficiency	  was	  greatly	  improved	  to	  above	  80%.	  Aside	  from	  conjugation	  optimization,	  the	  ENP	  precipitation	  procedure	  was	  also	  enhanced.	  The	  original	  precipitation	  method	  with	  ethanol	  showed	  significant	  ENP	   loss.	  A	  number	   of	   different	   solvents	   and	   additives	   were	   tested	   to	   enhanced	   ENP	   recovery.	   The	  final	   precipitation	  method	  was	  modified	   to	   co-­‐precipitation	   conjugated	   ENPs	  with	  MgCl2	  salt.	  	  With	   the	   ENPs	   fully	   modified,	   the	   final	   study	   focused	   on	   evaluating	   the	   vehicle’s	  capability.	   Vehicle	   cellular	   internalization	   and	   vehicle	   selectivity	   were	   investigated	   and	  observed	  using	   fluorescence	  microscopy.	   Initial	   epifluorescence	  microscopy	   results	  were	  crude	   and	   produced	   no	   conclusive	   evidence.	   A	   different	   imaging	   and	   staining	   technique	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were	   tested	   and	   the	   resulting	   images	   showed	   significant	   improvement.	   Initial	  internalization	  assay	  confirmed	  cellular	  internalization	  for	  aptamer-­‐modified	  ENPs,	  and	  the	  dye-­‐modified	   ENPs	   also	   displayed	   significant	   internalization.	   Dual-­‐labeled	   vehicle	   assay	  further	  confirmed	  internalization	  with	  co-­‐localized	  ENPs	  and	  aptamer	  fluorescence.	  Vehicle	  selectivity	  was	  validated	  through	  HeLa	  cells’	  preferential	  uptake	  of	  AS1411-­‐modified	  ENPs	  over	  sgc8-­‐modified	  ENPs.	  Lastly,	  aptamer-­‐modified	  ENPs	  were	  subjected	  to	  benchmarking	  against	   aptamer-­‐modified	   liposomes.	   Benchmarking	   results	   showed	   significantly	   higher	  uptake	  efficiency	  for	  liposomes	  over	  ENPs.	  	  	  
5.2	  Recommendations	  The	  results	  described	  in	  this	  thesis	  show	  great	  potential	  for	  aptamer-­‐modified	  ENPs	  as	  a	   targeted	  anti-­‐cancer	  drug	  delivery	  vehicle.	  However,	   further	  studies	  are	  needed	  to	   fully	  understand	  and	  improve	  the	  vehicle’s	  performance.	  The	  author	  recommends	  the	  following	  four	   aspects	   for	   future	   works:	   1)	   modified	   vehicle	   characterization,	   2)	   drug	   loading	  efficiency	  and	  release	  profile,	  3)	  quantitative	  analysis	  for	  cellular	  internalization	  using	  flow	  cytometry,	  4)	  selectivity	  test	  using	  different	  cell	  lines	  and	  the	  corresponding	  aptamers	  and	  5)	  perform	  vehicle	  modification	  using	  larger	  ENP.	  	  	  1)	  Modified	  vehicle	  characterization	  	  Vehicle	  characterization	  such	  as	  size	  and	  ζ-­‐potential	  measurements	  was	  only	  done	  with	  the	   oxidized	   ENP	   samples.	   Similar	   measurements	   for	   the	   aptamer-­‐modified	   ENPs	   are	  essential	  to	  better	  comprehend	  their	  fundamental	  property.	  Vehicle	  toxicity	  should	  also	  be	  investigated.	   Toxicity	   studies	   on	   non-­‐modified	   ENPs	   suggest	   no	   obvious	   cytotoxicity.	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However,	   after	   numerous	  modifications,	   it	   is	   possible	   for	   the	   resulting	   vehicle	   to	   have	   a	  negative	  effect	  on	  cell	  proliferation.	  	  	  2)	  Drug	  loading	  efficiency	  and	  release	  profile	  	  As	  a	  drug	  delivery	  platform,	  one	  of	   the	  major	  objectives	   is	   the	  ability	   to	   incorporate	  therapeutic	  molecules	   and	   achieve	   sustained	   release.	   It	   is	   a	   common	   practice	   for	   a	   drug	  delivery	  study	  to	  investigate	  the	  vehicle’s	  encapsulation	  efficiency	  and	  establish	  its	  release	  profile.	  A	  popular	  model	  drug	  for	  such	  study	  is	  doxorubicin	  due	  to	  its	  fluorescence.	  	  	  3)	  Quantitative	  analysis	  for	  cellular	  internalization	  	  All	   of	   the	   internalization	   assays	   presented	   in	   this	   thesis	   produced	   only	   qualitative	  evidence.	  Quantitative	  analysis	  was	  attempted	  by	  measuring	  the	  fluorescence	   intensity	   in	  the	  medium	   after	   internalization	   test,	   but	   the	   results	  were	   inconclusive.	   Flow	   cytometry	  utilized	  single	  cell	  counting	  technique	  to	  more	  accurately	  quantify	  cellular	  internalization.	  	  	  4)	  Selectivity	  test	  using	  different	  cell	  lines	  and	  the	  corresponding	  aptamers	  	  All	  of	  the	  internalization	  assays	  and	  selectivity	  assay	  presented	  in	  this	  thesis	  were	  done	  using	   HeLa	   cells.	   To	   further	   emphasize	   the	   vehicle’s	   selectivity,	   separate	   ENP	   samples	  modified	  with	  different	  aptamers	  and	  dyes	  can	  be	  incubated	  with	  cell	  samples	  containing	  different	  cell	  lines.	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5)	  Vehicle	  modification	  using	  larger	  ENP	  The	   molecular	   weight	   of	   ENP	   is	   around	   106	   Dalton	   from	   our	   collaborators.	   The	  molecular	  weight	  of	  AS1411	  is	  around	  12000	  Dalton.	  Therefore,	  if	  one	  ENP	  is	  conjugated	  to	  just	   one	   aptamer,	   the	  weight	   of	   aptamer	   needed	   is	   1.2%	   of	   the	   ENP.	   If	   we	   consider	   the	  coupling	   efficiency	   and	   if	   more	   than	   one	   DNA	   is	   attached	   to	   each	   ENP,	   the	   mass	   ratio	  between	   aptamer	   and	   ENP	   is	   likely	   to	   go	   over	   1:100.	   While	   ENP	   is	   cost-­‐effective,	   the	  aptamer	   is	   more	   costly.	   Therefore,	   it	   might	   be	   necessary	   to	   engineer	   higher	   molecular	  weight	  ENP	  to	  decrease	  the	  usage	  of	  aptamer.	  	  	   	  
	  	   63	  
References	  1. Cooper,	   G.M.	   Elements	   of	   Human	   Cancer;	   Jones	   and	   Bartlett	   Publishers:	   Boston,	  1992.	  	  2. Stewart,	   B.W.;	   Wild,	   C.P.	   World	   Cancer	   Report	   2014.	   International	   Agency	   for	  Research	  on	  Cancer:	  Lyon,	  2014	  
3. Boyle,	  P.;	  Levin,	  B.	  World	  Cancer	  Report	  2008.	  International	  Agency	  for	  Research	  on	  Cancer:	  Lyon,	  2008.	  4. Cancer	  Facts	  &	  Figures	  2012.	  American	  Cancer	  Society:	  Atlanta,	  2012.	  	  5. Jemal,	   A.;	   Bray,	   F.;	   Center,	   M.M.;	   Ferlay,	   J.;	   Ward,	   E.;	   Forman,	   D.	   Global	   Cancer	  Statistics.	  CA	  A	  Cancer	  Journal	  for	  Clinicians.	  2011,	  21,	  69-­‐90.	  6. Miller,	   A.B.;	   Hoogstraten,	   B.;	   Staquet,	   M.;	   Winkler,	   A.	   Reporting	   results	   of	   cancer	  treatment.	  Cancer.	  1981,	  47,	  207-­‐214.	  7. Hajdu,	   S.I.	   A	   note	   from	   history:	   landmarks	   in	   history	   of	   cancer,	   part	   4.	   Cancer.	  
2012,118,4914-­‐4928.	  	  	  8. Wood,	   W.	   X-­‐rays	   in	   the	   treatment	   of	   cancer	   and	   other	   malignant	   diseases.	   The	  Medical	  Record.	  1902,	  62,	  692-­‐695.	  	  	  9. Rak,	   J.;	   Chomicz,	   L.;	  Wiczk,	   J.;	  Westphal,	  K.;	   Zdrowowicz,	  M.;	  Wityk,	   P.;	   Zyndul,	  M.;	  Makurat,	   S.;	   Golon,	   L.	   Mechanisms	   of	   damage	   to	   DNA	   labeled	   with	   electrophilic	  nucleobases	  induced	  by	  ionizing	  or	  UV	  radiation.	  The	  Journal	  of	  Physical	  Chemistry.	  
2015,	  119,	  8227-­‐8238.	  	  10. Kerr,	  J.F.R.;	  Winterford,	  CM.;	  Harmon,	  B.V.	  Apoptosis	  –	  Its	  significance	  in	  cancer	  and	  cancer	  therapy.	  Cancer.	  1994,	  73,	  2013-­‐2026.	  
	  	   64	  
11. Karnofsky,	   D.A.;	   Walter,	   H.A.;	   Lloyd,	   F.C.;	   Joseph,	   H.B.	   The	   use	   of	   the	   nitrogen	  mustards	   in	   the	   palliative	   treatment	   of	   carcinoma.	   With	   particular	   reference	   to	  bronchogenic	  carcinoma.	  Cancer.	  1948,	  1,	  634-­‐656.	  	  12. Hegi,	  M.E.;	  Diserens,	  A.;	  Gorlia,	  T.;	  Hamou,	  M.;	  de	  Tribolet,	  N.;	  Weller,	  M.;	  Kros,	  J.M.;	  Hainfellner,	   J.A.;	  Mason,	  W.;	  Mariani,	  L.;	  Bromberg,	   J.E.C.;	  Hau,	  P.;	  Mirimanoff,	  R.O.;	  Cairncross,	   J.G.;	   Janzer,	   R.C.;	   Stupp,	   R.	   MGMT	   gene	   silencing	   and	   benefit	   from	  temozolomide	   in	   glioblastom.	   New	   England	   Journal	   of	   Medicine.	  2005,	   352,	   997-­‐1003.	  13. Kaufmann,	   S.H.;	   Earnshaw,	   W.C.	   Induction	   of	   apoptosis	   by	   cancer	   chemotherapy.	  Experimental	  Cell	  Research.	  2000,	  256,4	  2-­‐49.	  	  14. Liu,	   J.F.;	   DNA	   topoisomerase	   poisons	   as	   antitumor	   drugs.	   Annual	   Review	   of	  Biochemistry.	  1989,	  58,	  351-­‐375.	  15. Gibson,	   R.J.;	   Keefe,	   D.M.	   Cancer	   chemotherapy-­‐induced	   diarrhea	   and	   constipation:	  mechanisms	  of	  damage	  and	  prevention	  strategies.	  Supportive	  Care	  in	  Cancer.	  2006,	  24,	  890-­‐900.	  	  16. Neog,	   B.;	   Sinha,	   S.;	   Bhttacharyya,	   P.K.	   Alkylation	   of	   DNA	   by	   nitrogen	  mustards:	   A	  DFT	  study.	  Computational	  and	  Theoretical	  Chemistry.	  2013,	  1018,	  19-­‐25.	  	  17. Jordan,	   K;	   Sippel,	   C.;	   Schmoll,	   H.J.	   Guidelines	   for	   antiemetic	   treatment	   of	  chemotherapy-­‐induced	   nausea	   and	   vomiting:	   past	   present	   and	   future	  recommendations.	  Oncologist.	  2007,	  12,	  1143-­‐1150.	  	  18. Katzel,	  J.A.;	  Fanucchi,	  M.P.	  Recent	  advances	  of	  novel	  targeted	  therapy	  in	  non0small	  cell	  lung	  cancer.	  Journal	  of	  Hematology	  &	  Oncology.	  2009,	  2,	  1-­‐18.	  	  
	  	   65	  
19. Ducry,	   L.;	   Stump,	   B.	   Antibody-­‐drug	   conjugates:	   linking	   cytotoxic	   payloads	   to	  monoclonal	  antibodies.	  Bioconjugate	  Chemistry.	  2010,	  21,	  5-­‐13.	  	  20. Stephen,	   C.A.;	   Nicole,	   M.O.;	   Peter,	   D.S.	   Antibody-­‐drug	   conjugates:	   targeted	   drug	  delivery	  for	  cancer.	  Current	  Opinion	  in	  Chemical	  Biology.	  2010,	  14,	  529-­‐537.	  	  21. Peters,	  G.J.;	  van	  der	  Wilt,	  C.L.;	  Van	  Moorsel,	  C.J.A.;	  Kroep,	  J.R.;	  Bergman,	  A.M.;	  Ackland,	  S.P.	   Basis	   for	   effective	   combination	   cancer	   chemotherapy	   with	   antimetabolites.	  Pharmacology	  &	  Therapeutics.	  2000,	  87,	  227-­‐253.	  	  22. Lam,	   P.L.;	   Gambari,	   R.	   Advanced	   progress	   of	   microencapsulation	   technologies:	   in	  vivo	  and	  in	  vitro	  models	  for	  studying	  oral	  and	  transdermal	  drug	  deliveries.	  Journal	  of	  Controlled	  Release.	  2014,	  178,	  25-­‐45.	  23. Brannon-­‐Peppas,	   L.;	   Blanchette,	   J.O.	  Nanoparticle	   and	   targeted	   systems	   for	   cancer	  therapy.	  Advanced	  Drug	  Delivery	  Reviews.	  2004,	  56,	  1649-­‐1659.	  	  24. Jong,	   D.W.;	   Borm,	   J.A.	   Drug	   Delivery	   and	   nanoparticles:	   Applications	   and	   hazards.	  International	  Journal	  of	  Nanomedicine.	  2008,	  2,	  133-­‐149.	  25. Ferrari,	   M.	   Cancer	   nanotechnology:	   opportunities	   and	   challenges.	   Nature	   Review	  Cancer.	  2005,	  5,	  161-­‐171.	  26. Ishida,	  T.;	  Harashima,	  H.;	  Kiwada,	  H.	  Liposome	  clearance.	  Bioscience	  Reports.	  2002,	  22,	  197-­‐224.	  	  27. Li,	  X.;	  Yu,	  Y.;	  Ji,	  Q.;	  Qiu,	  L.Y.	  Targeted	  delivery	  of	  anticancer	  drugs	  by	  aptamer	  AS1411	  mediated	   Pluronic	   F127/cyclodextrin-­‐linked	   polymer	   composite	   micelles.	  Nanomedicine-­‐Nanotechnology	  Biology	  and	  Medicine.	  2015,	  11,	  175-­‐184.	  	  
	  	   66	  
28. Gujral,	   S.;	   Khatri,	   S.	   A	   review	   on	   basic	   concept	   of	   drug	   targeting	   and	   drug	   carrier	  system.	   International	   Journal	   of	   advances	   in	   Pharmacy,	   Biology	   and	   Chemistry.	  
2013,	  2,	  130-­‐136.	  	  29. Duncan,	  R.;	  Sat,	  Y.	  Tumour	  targeting	  by	  enhanced	  permeability	  and	  retention	  (EPR)	  effect.	  Annals	  of	  Oncology.	  1998,	  39.	  30. Greish,	   K.	   Enhanced	   permeability	   and	   retention	   effect	   for	   selective	   targeting	   of	  anticancer	  nanomedicine:	  Are	  we	   there	  yet?	  Drug	  Discovery	  Today.	  2012,	   9,	   161-­‐166.	  31. Maeda,	  H.;	  Wu,	  J.;	  Sawa,	  T.;	  Matsumura,;	  Y.	  Hori,	  K.	  Tumor	  vascular	  permeability	  and	  the	   EPR	   effect	   in	   macromolecular	   therapeutics:	   a	   review.	   Journal	   of	   Controlled	  Release.	  2000,	  65,	  271-­‐284.	  	  32. Lembo,	  D.;	  Cavalli,	  R.	  Nanoparticulate	  delivery	  systems	  for	  antiviral	  drugs.	  Antiviral	  Chemistry	  &	  Chemotherapy.	  2010,	  21,	  53-­‐70.	  	  33. Lembo,	  D.;	  Cavalli,	  R.	  Review	  –	  Nanoparticulate	  delivery	  systems	  for	  antiviral	  drugs.	  Antiviral	  Chemistry	  &	  Chemotherapy.	  2010,21,53-­‐70.	  34. Torchilin,	   V.P.;	   Klibanov,	   A.L.;	   Huang,	   L.;	   O’Donnell,	   S.;	   Nossiff,	   N.D.;	   Khaw;	   B.A.	  Targeted	   accumulation	   of	   polyethylene	   glycol-­‐coated	   immunopiposomes	   in	  infracted	   rabbit	  myocardium.	  The	   Journal	   of	   the	   Federation	  of	  American	   Societies	  for	  Experimental	  Biology.	  1992,	  6,	  2716-­‐2719.	  35. Bies,	   C.;	   Lehr,	   C.;	   Woodley,	   F.	   J.	   Lectin-­‐mediated	   drug	   targeting:	   history	   and	  applications.	  Advanced	  Drug	  Delivery	  Reviews.	  2004,56,425-­‐435.	  36. Torchilin,	   V.P.	   Passive	   and	   active	   drug	   targeting:	   drug	   delivery	   to	   tumors	   as	   an	  example.	  Handbook	  of	  Experimental	  Pharmacology.	  2010,	  197,	  3-­‐53.	  
	  	   67	  
37. Xiao,	   S.;	   Tong,	   C.;	   Liu,	   X.;	   Yu,	   D.;	   Liu,	   Q.;	   Xue,	   C.;	   Tang,	   D.;	   Zhao,	   L.	   Preparation	   of	  folate-­‐conjugated	   starch	   nanoparticles	   and	   its	   application	   to	   tumor-­‐targeted	   drug	  delivery	  vector.	  Chinese	  Science	  Bulletin.	  2006,	  51,	  1693-­‐1697.	  	  38. Li,	   Xin.;	   Zhao,	   Q.;	   Qiu,	   L.	   Smart	   ligand:	   aptamer	   –mediated	   targeted	   delivery	   of	  chemotherapeutic	   drugs	   and	   siRNA	   for	   cancer	   therapy.	   Journal	   of	   Controlled	  Release.	  2013,	  171,	  152-­‐162.	  	  39. Veli	   C.	   Ozlp	   and	   Thomas	   Schafer	   (2012).	   Aptamer-­‐Nanoparticle	   Bioconjugates	   for	  Drug	  Delivery,	  The	  Delivery	  of	  Nanoparticles,	  Dr.	  Abbass	  A.	  Hashim	  (Ed.),	  ISBN:	  978-­‐953-­‐51-­‐0615-­‐9.	  In	  Tech.	  40. Brannon-­‐Peppas,	   L.;	   Blanchette,	   J.O.	  Nanoparticle	   and	   targeted	   systems	   for	   cancer	  therapy.	  Advanced	  Drug	  Delivery	  Reviews.	  2012,	  64,	  206-­‐212.	  41. Lee,	   J.H.;	   Yigit,	   M.V.;	  Mazumdar,	   D.;	   Lu,	   Y.	  Molecular	   diagnostic	   and	   drug	   delivery	  agents	   based	   on	   aptamer-­‐nanomaterial	   conjugates.	   Advanced	   Drug	   Delivery	  Reviews.	  2010,62,592-­‐605.	  	  42. Yang,	  L.;	  Zhang,	  X.;	  Ye,	  M.;	  Jiang,	  J.;	  Yang,	  R.;	  Fu,	  T.;	  Chen,	  Y.;	  Wang,	  K.;	  Liu,	  C.;	  Tan,	  W.	  Aptamer-­‐conjugated	  nanomaterials	  and	  their	  applications.	  Advanced	  Drug	  Delivery	  Reviews.	  2011,	  63,	  1361-­‐1370.	  43. Lee,	   J.H.;	   Yigit,	   M.V.;	  Mazumdar,	   D.;	   Lu,	   Y.	  Molecular	   diagnostic	   and	   drug	   delivery	  agents	   based	   on	   aptamer-­‐nanomatierls	   conjugates.	   Advanced	   Drug	   Delivery	  Reviews.	  2010,	  62,	  592-­‐605.	  	  44. Darmostuk,	  M.;	  Rimpelova,	  S.;	  Gbelcova,	  H.;	  RumL,	  T.	  Current	  approaches	  in	  SELEX:	  An	  update	  to	  aptamer	  selection	  technology.	  Biotechnology	  Advances.	  2015.	  	  
	  	   68	  
45. 	  Zamboni,	  W.C.	   Liposomal,	   nanoparticle,	   and	   conjugated	   formulation	   of	   anticancer	  agents.	  Clinical	  Cancer	  Research.	  2005,	  11,	  8230-­‐8234.	  	  46. Matsumura,	   Y.;	   Maeda,	   H.	   A	   new	   concept	   of	   macromolecular	   therapies	   in	   cancer	  chemotherapy:	   mechanism	   of	   tumortropic	   accumulation	   of	   proteins	   and	   the	  antitumor	  agent	  SMANCS.	  Cancer	  Research.	  1986,	  6,	  6387-­‐6392.	  	  47. Hong,	  S.;	  Leroueil,	  P.R.;	  Majoros,	  I.J.;	  Orr,	  B.G.;	  Baker,	  J.R.Jr.;	  Banaszak	  Holl,	  M.M.	  The	  binding	  avidity	  of	  a	  nanoparticle-­‐based	  multivalent	  targeted	  drug	  delivery	  platform.	  Chemistry	  &	  Biology.	  2007,	  14,	  107-­‐115.	  	  48. Bartlett,	  D.W.;	  Davis,	  M.E.	  Physiochemical	  and	  biological	  characterization	  of	  targeted,	  nucleic	  acid-­‐containing	  nanoparticles.	  Bioconjugate	  Chemistry.	  2007,	  18,	  456-­‐468.	  	  49. Allen,	   T.M.;	   Cullis,	   P.R.	   Liposomal	   drug	   delivery	   systems:	   From	   concept	   to	   clinical	  applications.	  Advanced	  Drug	  Delivery	  Reviews.	  2013,65,36-­‐48.	  50. Dunne,	  M.;	   Zheng,	   J.;	   Rosenblat,	   J.;	   Jaffray,	   D.A.;	   Allen,	   C.	   APN/CD13-­‐targeting	   as	   a	  strategy	  to	  alter	  the	  tumor	  accumulation	  of	  liposomes,	  Journal	  of	  Controlled	  Release.	  
2011,142,298-­‐305.	  51. Torchilin,	   V.P.	   Recent	   advances	   with	   liposomes	   as	   pharmaceutical	   carriers.	   Drug	  Discovery.	  2005,	  4,	  145-­‐160.	  	  52. Pisano,	  C.;	  Cecere,	  S.C.;	  Napoli,	  M.D.;	  Cavaliere,	  C.;	  Tambaro,	  R.;	  Facchini,	  G.;	  Scaffa,	  C.;	  Losito,	   S.;	   Pizzolorusso,	   A.;	   Pignata,	   S.	   Clinical	   trials	   with	   peglated	   liposomal	  doxorubicin	   in	   the	   treatment	   of	   ovarian	   cancer.	   Journal	   of	   Drug	   Delivery.	   2013,	  2013,	  1-­‐12.	  	  
	  	   69	  
53. Scott,	  R.;	  Crabbe,	  D.;	  Krynska,	  B.;	  Ansari,	  R.;	  Kiani,	  Mohammad.	  Aiming	  for	  the	  heart:	  targeted	   delivery	   of	   drugs	   to	   diseased	   cardiac	   tissue.	   Expert	   Opinion	   on	   Drug	  Delivery.	  2008,	  5,	  459-­‐470.	  54. O’Shaughnessy,	   J.A.	   Pegylated	   liposomal	   doxorubicin	   in	   the	   treatment	   of	   breast	  cancer.	  Clinical	  Breast	  Cancer.	  2003,	  4,	  318-­‐328.	  	  55. Fuertges,	  F.;	  Abuchowski,	  A.	  The	  clinical	   efficacy	  of	  poly(ethylene	  glycol)	  modified	  proteins.	  Journal	  of	  Controlled	  Release.	  1990,	  11,	  139-­‐148.	  	  56. Davis,	  M.E.;	   Chen,	   Z.;	   Shin,	  D.M.	  Nanoparticle	   therapeutics:	   an	   emerging	   treatment	  modality	  for	  cancer.	  Drug	  Discovery.	  2008,	  7,	  771-­‐782.	  57. Zebel,	  H.F.;	  Stephen,	  A.M.	  Starch:	  structure,	  analysis	  and	  application;	  Marcel	  Dekker:	  New	  York,	  1996.	  58. Tester,	  R.F.;	  Karkalas,	  J.	  Polysaccharides	  from	  eukaryotes;	  Wiley:	  Weinheim,	  2002.	  	  59. Tester,	  R.F.;	  Karkalas,	  J.;	  Qi,	  X.	  Starch	  –	  composition,	  fine	  structure	  and	  architecture.	  Journal	  of	  Cereal	  Science.	  2004,	  39,	  151-­‐165.	  60. Gallant,	  D.J.;	  Bouchet,	  B.;	  Baldwin,	  P.M.	  Microscopy	  of	  starch:	  evidence	  of	  a	  new	  level	  of	  granule	  organization.	  Carbohydrate	  Polymers.	  1997,	  32,	  177-­‐191.	  	  61. Le	   Corre,	   D.;	   Bras,	   J.;	   Dufresne,	   Alain.	   Starch	   Nanoparticles:	   A	   Review.	  Biomacromolecules.	  2010,	  11,	  1139-­‐1153.	  62. Yamamoto,	   M.;	   Takahashi,	   Y.;	   Tabata,	   Y.	   Controlled	   release	   by	   biodegradable	  hydrogels	   enhances	   the	   ectopic	   bone	   formation	   of	   bone	   morphogenetic	   protein.	  Biomaterials.	  2003,24,4375-­‐4383.	  
	  	   70	  
63. Bhattarai,	   N.;	   Ramay,	   H.R.;	   Chou,	   S.H.;	   Zhang,	   M.	   Chitosan	   and	   lactic	   acid-­‐grafted	  chitosan	   nanoparticles	   as	   carriers	   for	   prolonged	   drug	   delivery.	   Journal	   of	  International	  Journal	  of	  Nanomedicine.	  2006,	  2,	  181-­‐187.	  	  64. Naahidi,	   S.;	   Jafari,	   M.;	   Edalat,	   M.;	   Raymond,	   L.;	   Khademhosseini,	   A.;	   Chen,	   P.	  Biocompatibility	   of	   engineered	   nanoparticles	   for	   drug	   delivery.	   Journal	   of	  Controlled	  Release.	  2013,	  166,	  182-­‐194.	  65. Liu,	  Z.;	  Jiao,	  Y.;	  Wang,	  Y.;	  Zhou,	  C.;	  Zhang,	  Z.	  Polysaccharides-­‐based	  nanoparticles	  as	  drug	  delivery	  systems.	  Advance	  Drug	  Delivery	  Reviews.	  2008,	  60,	  1650-­‐1662.	  	  66. Chen,	  S.;	  Liu,	  M.;	  Jin,	  S.;	  Wang,	  B.	  Preparation	  of	  ionic-­‐crosslinked	  chitosan-­‐based	  gel	  beads	   and	   effect	   of	   reaction	   condition	   on	   drug	   release	   behaviors.	   International	  Journal	  of	  Pharmaceutics.	  2008,	  349,	  180-­‐187.	  	  67. Tang,	  Y.;	  Xiao,	  S.;	  Zhang,	  J.;	  Guo,	  D.;	  Kong,	  F.;	  Zhang,	  N.	  Extraction	  of	  cellulose	  nano-­‐crystals	   from	  old	   corrugated	   container	   fiber	  using	  phosphoric	   acid	   and	   enzymatic	  hydrolysis	  followed	  by	  sonication.	  Carbohydrate	  Polymers.	  2015,	  125,	  360-­‐366.	  	  68. Ahmad,	  Z.;	  Khuller,	  G.K.	  Alginate-­‐based	  sustained	  release	  drug	  delivery	  systems	  for	  tuberculosis.	  Expert	  Opinion	  Drug	  Delivery.	  2008,	  5,	  1323-­‐1334.	  69. Kim,	   K.;	   Kwon,	   S.;	   Park,	   J.H.;	   Chung,	   H.;	   Jeong,	   S.Y.;	   Kwon,	   I.C.;	   Kim,	   I.S.	  Physiochemical	  characterization	  of	  self-­‐assembled	  nanoparticles	  of	  glycol	  chitosan-­‐deoxycholic	  acid	  conjugates.	  Biomacromolecules.	  2005,	  6,	  1154-­‐1158.	  70. Santander-­‐Ortega,	  M.J.;	  Stauner,	  T.;	  Loretz,	  B.;	  Ortega-­‐Vinuesa,	  J.L.;	  Bastos-­‐Gonzalez,	  D.;	   Wenz,	   G.;	   Schaefer,	   U.F.;	   Lehr,	   C.M.	   Nanoparticles	   made	   from	   novel	   starch	  derivatives	  for	  transdermal	  drug	  delivery.	  Journal	  of	  Controlled	  Release.	  2010,	  141,	  85-­‐92.	  
	  	   71	  
71. Tuovinen,	  L.;	  Ruhanen,	  E.;	  Kinnarinen,	  T.;	  Ronkko,	  S.;	  Pelkonen,	  J.;	  Urtii,	  A.;	  Peltonen,	  S.;	   Jarvinen,	  K.	  Starch	  acetate	  microparticles	   for	  drug	  delivery	   into	  retinal	  pigment	  epithelium	  –	  in	  vitro	  study.	  Journal	  of	  Controlled	  Release.	  2004,	  98,	  407-­‐413.	  	  72. Tuovinen,	   L.;	   Peltonen,	   S.;	   Jarvinen,	   K.	   Drug	   release	   from	   starch-­‐acetate	   films.	  Journal	  of	  Controlled	  Release.	  2003,	  91,	  345-­‐354.	  	  73. Wang,	  S.;	  Copeland,	  L.	  Effect	  of	  acid	  hydrolysis	  on	  starch	  structure	  and	  functionality:	  A	  review.	  Food	  Science	  and	  Nutrition.	  2015,	  55,	  1079-­‐1095.	  	  74. Kim,	   J.Y.;	   Park,	   D.J.;	   Lim,	   S.T.	   Fragmentation	   of	   waxy	   rice	   starch	   granules	   by	  enzymatic	  hydrolysis.	  Cereal	  Chemistry.	  2008,	  85,	  182-­‐187.	  	  75. Liu,	  D.;	  Wu,	  Q.;	   Chen,	  H.;	   Chang,	  P.R.	  Transitional	  properties	  of	   starch	   colloid	  with	  particle	   size	   reduction	   from	  micro	   to	   nanometer.	   Journal	   of	   Colloid	   and	   Interface	  Science.	  2009,	  339,	  117-­‐124.	  	  76. Kim,	  H.Y.;	  Park,	  S.S.;	  Lm,	  S.T.	  Preparation,	  characterization	  and	  utilization	  of	  starch	  nanoparticles.	  Colloids	  and	  Surfaces	  B:	  Biointerfaces.	  2015,	  126,	  607-­‐620.	  	  77. Bloembergen,	  S.;	  McLennan,	  I.;	  Lee,	  D.I.;	  van	  Leeuwen,	  J.	  A	  starch-­‐based	  biolatex	  can	  replace	   petroleum-­‐based	   latex	   binders	   in	   papermaking.	   The	   Technological	  Association	  of	  the	  Pulp	  and	  Paper	  Industry	  Journal.	  2008,	  46-­‐48.	  	  78. Klass,	  C.	  New	  nanoparticle	  laytex	  offers	  natural	  advantage.	  Paper	  360°.	  2007,	  30-­‐31.	  	  79. Lai,	   L.S.;	   Kokini,	   J.L.	   The	   effect	   of	   extrusion	   operating	   conditions	   on	   the	   on-­‐line	  apparent	  viscosity	  of	  98%	  amylopectin	  (Amioca)	  and	  70%	  amylose	  (Hylon	  7)	  corn	  starches	  during	  extrusion.	  Journal	  of	  Rheology.	  1990,	  34,	  1245-­‐1266.	  	  80. Li,	  D.M.H	  Characterization,	  quantification	  and	  modification	  of	  starch	  nanoparticles.	  University	  of	  Waterloo,	  2014.	  
	  	   72	  
81. Agnihotri,	   S.A.;	  Mallikarjuna,	  N.N.;	   Aminabhavi,	   T.M.	  Recent	   advances	   on	   chitosan-­‐based	   micro-­‐	   and	   nanoparticles	   in	   drug	   delivery.	   Journal	   of	   Controlled	   Release.	  
2004,100,5-­‐28.	  82. Jones,	  N.;	  Wagner,	  R.;	  Shermon,	  A.;	  Ip,	  A.;	  El-­‐Hamed,	  F.;	  McLennan,	  I.;	  Bloembergen,	  S.;	   Liu,	   J.	   Targeted	   drug	   delivery	   using	   aptamer	   functionalized	   crosslinked	   starch	  nanoparticles.	  83. Kato,	  Y.;	  Matsuo,	  R.;	  Isogai,	  A.	  Oxidation	  process	  of	  water-­‐soluble	  starch	  in	  TEMPO-­‐mediated	  system.	  Carbohydrate	  Polymers.	  2003,51,69-­‐75.	  84. Isogai,	  A.;	   Saito,	  T.;	   Fukuzumi,	  H.	  TEMPO-­‐oxidized	   cellulose	  nanofibers.	  Nanoscale.	  
2011,	  3,	  71-­‐85.	  	  85. Chang,	   P.S.;	   Rpbyt,	   J.F.	   Oxidation	   of	   primary	   alcohol	   groups	   of	   naturally	   occurring	  polysaccharides	   with	   2,2,6,6,-­‐tetramethyl-­‐1-­‐piperidine	   oxoammonium	   ion.	   Journal	  of	  Carbohydrate	  Chemistry.	  1996,15,819-­‐830.	  	  86. Hirota,	   M.;	   Tamura,	   N.;	   Saito,	   T.;	   Iogai,	   A.	   Oxidation	   of	   regenerated	   cellulose	  with	  NaClO2	  catalyzed	  by	  TEMPO	  and	  NaClO	  under	  acid-­‐neutral	  conditions.	  Carbohydrate	  Polymers.	  2009,	  78,	  330-­‐335.	  	  87. Jones,	   N.;	   Wagner,	   R.;	   Shermon,	   A.;	   Ip,	   A.C.F.;	   El-­‐Hamed,	   F.;	   McLennan,	   I.J.;	  Bloembergen,	  S.;	  Liu,	  J.;	  Targeted	  delivery	  using	  aptamer	  functionalized	  crosslinked	  starch	  nanoparticles.	  	  88. Yaghoubi,	   H.;	   Khajeh,	   K.;	   Hosseinkhani,	   S.;	   Ranjbar,	   B.;	   Naderi-­‐Manesh,	   H.	  Application	   of	   zero-­‐length	   cross-­‐linking	   to	   form	   lysozyme,	   horseradish	   peroxidae	  andlysozyme-­‐peroxidase	   dimers:	   activity	   and	   stability.	   International	   Journal	   of	  Biological	  Macromolecules.	  2007,	  41,	  624-­‐630.	  	  
	  	   73	  
89. Gilles	  M.A.;	   Hudson,	   A.Q.;	   Borders,	   C.L.	   Stability	   of	  water-­‐soluble	   carbodiimides	   in	  aqueous	  solution.	  Analytical	  Biochemistry.	  1990,184,244-­‐248.	  	  90. Hermanson,	  G.T.	  Bioconjugate	  Techniques	  2nd	  Edition;	  Elsevier:	  USA,	  2008;	  p215-­‐223.	  91. 	  Butler,	   J.S.;	   Lee,	   J.H.;	   Skalnik,	   D.G.	   PAGE	   separation	   of	   hemi-­‐methylated	   or	  unmethylated	   oligonucleotide	   substrates	   to	   distinguish	   between	  maintenance	   and	  de	   novo	   DNA	   methyltransferase	   activity.	   Journal	   of	   Biochemical	   and	   Biophysical	  Methods.	  2006,	  68,	  195-­‐199.	  	  92. Mangalam,	   A.P;	   Simonsen,	   J.;	   Benight,	   A.S.	   Cellulose/DNA	   Hydrid	   Nanomaterials.	  Biomacromolecules.	  2009,10,497-­‐504.	  	  93. 	  	  Ip,	  A.C.F.;	  Tsai,	  T.H.;	  Khimji,	   I.;	  Huang,	  P.J.J.;	  Liu,	   J.	  Degradable	  starch	  nanoparticle	  assisted	  ethanol	  precipitation	  of	  DNA.	  Carbohydrate	  polymers.	  2014,	  110,	  354-­‐359.	  	  94. Gaillard,	  C.;	   Strauss,	  F.	  Ethanol	  precipitation	  of	  DNA	  with	   linear	  polyacrylamide	  as	  carrier.	  Nucleic	  Acids	  Research.	  1990,	  18,	  378.	  95. 	  Ni,	  X.H.;	  Castanares,	  M.;	  Mukherjee,	  A.;	  Lupold,	  S.E.	  Nucleic	  acid	  aptamers:	   clinical	  applications	  and	  promising	  new	  horizons.	  Current	  Medicinal	  Chemistry.	  2011,	   18,	  4206-­‐4214.	  96. Soundararajan,	  S.;	  Chen,	  W.;	  Spicer,	  E.K.;	  Courtenay	  –Luck,	  N.;	  Gernandes,	  D.J.;	  The	  nucleolin	   targeting	   aptamer	   AS1411	   destabilized	   Bcl-­‐2	  messenger	   RNA	   in	   human	  breast	  cancer	  cells.	  Cancer	  Research.	  2008,	  68,	  2358-­‐2365.	  97. Hwang	  do,	  W.;	  Ko,	  H.Y.;	  Lee,	   J.H.;	  Kang,	  H.;	  Ryu,	  S.H.;	   Song,	   I.C.;	  Lee,	  D.S.;	  Kim,	  S.	  A	  nucleolin-­‐targeted	  multimodal	  nanoparticle	   imaging	  proge	   for	   tracking	   caner	   cells	  using	  an	  aptamer.	  Journal	  of	  Nuclear	  Medicine.	  2010,	  51,	  98-­‐105.	  	  
	  	   74	  
98. Ireson,	   C.R.;	   Kelland,	   L.R.	   Discovery	   and	   development	   of	   anticancer	   aptamers.	  Molecular	  Cancer	  Therapeutics.	  2006,	  5,	  2957-­‐2962.	  	  99. Hovanessian,	  A.G.;	  Puvion-­‐Dutilleul,	  F.;	  Nisole,	  S.;	  Svab,	  J.;	  Perret,	  E.;	  Deng,	  J.S.;	  Krust,	  B.	   The	   cell-­‐surface-­‐expressed	   nucleolin	   is	   associated	   with	   actin	   cytoskeleton.	  Experimental	  Cell	  Research.	  2000,	  261,	  312-­‐328.	  	  100. Shangguan,	  D.H.;	  Li,	  Y.;	  Tang,	  Z.;	  Cao,	  Z.C.;	  Chen,	  H.W.;	  Mallikaratchy,	  P.;	  Sefah,	  K.;	  Ynag,	  C.J.;	  Tan,	  W.	  Aptamers	  evolved	  from	  live	  cells	  as	  effective	  molecular	  probes	  for	  cancer	  study.	  Proceedings	  of	  the	  National	  Academy	  Sciences.	  2006,	  103,	  11838-­‐11843.	  	  
101. Xiao,	   Z.Y.;	   Shangguan	   D.H.;	   Cao,	   Z.H.;	   Fang,	   X.H.;	   Tan,	   W.H.	   Cell	   specific	  internalization	   study	   of	   an	   aptamer	   from	   whole	   cell	   selection.	   Chemistry-­‐A	  European	  Journal.	  2008,	  14,	  1769-­‐1775.	  	  
